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ABSTRACT 
 
Mechanistic Distinctions of Peripheral Neuropathies Induced  
via Microtubule-targeting Agents 
 
by 
 
Brett Michael Cook 
 
The overall goal of the experimental work undertaken in this thesis is to better 
understand the cellular and molecular mechanisms responsible for the onset, progression, 
and recovery from peripheral neuropathy, a painful and dose-limiting side effect of 
microtubule targeting agent (MTA) chemotherapies.  The frequency of severe peripheral 
neuropathy varies among the different MTAs, and since the microtubule binding interactions 
and mechanisms of action also vary, we hypothesized that these distinct mechanisms may 
underlie the variability in pathophysiology of chemotherapy induced peripheral neuropathy 
(CIPN).  
This work began with a correlative investigation of the morphological and 
biochemical effects that occur in peripheral nerves upon in-vivo treatment with MTAs in a 
maximum tolerated dose mouse model.  We analyzed sciatic nerves from mice treated with 
the chemotherapy drugs paclitaxel (frequent severe neuropathy) or eribulin (infrequent 
severe neuropathy) and found that morphologically, paclitaxel increased the frequency of 
observed signs of axon degeneration more significantly than did eribulin. Alternatively, 
eribulin but not paclitaxel induced occasional myelin "halo" structures. Biochemically, 
  x 
paclitaxel, and eribulin both induced α-tubulin expression (~1.9- and ~2.5-fold, respectively) 
and α-tubulin acetylation, a marker for microtubule stability, (~5- and ~11.7-fold, 
respectively). Eribulin but not paclitaxel-induced microtuble end-binding protein 1 (EB1) 
expression ~2.2-fold while paclitaxel but not eribulin mildly suppressed end-binding protein 
3 (EB3) expression. Both EB proteins are associated with microtubule growth. Eribulin's 
combination of relatively mild deleterious morphological effects coupled with more potent 
biochemical changes promoting microtubule stability and growth in mice correlate with 
lower frequencies of severe neuropathy in humans. We hypothesized that these eribulin-
induced effects created a relatively stable microtubule network that compensated, in part, for 
the toxic anti-cancer effects of the drug, leading to fewer reported incidences of peripheral 
neuropathy than for paclitaxel. 
We then extended these comparative studies to acquire a more detailed understanding of 
the resolution from these initial effects over the course of 6 months after the completion of 
either paclitaxel, eribulin, or ixabepilone dosing.  In paclitaxel-treated mice, axon area 
density was significantly decreased through 3 months of recovery.  In contrast, axon area 
density in eribulin-treated mice recovered fully from initial deficits by the 2 week time point, 
with ixabepilone showing no change at any time point. Evidence of myelin abnormalities, 
likely secondary to axonopathy, was prominent at 2 weeks and 3 months and was 
consistently most frequent in paclitaxel-treated animals. Also, only paclitaxel-treated mice 
displayed a significant and persistent increase in the number of non-neuronal nuclei at the 2 
week, 3 month and 6 month recovery time points, although ixabepilone-treated mice showed 
a similar trend at 2 weeks. These additional nuclei were positive for known Schwann cell 
markers S100B and GFAP, indicating that they are likely Schwann cells, the resident glia of 
the sciatic nerve. Biochemically, we found that two weeks into the recovery phase, α-tubulin 
  xi 
acetylation in eribulin-treated mice returned to control levels while it was greatly reduced 
but still significantly higher than vehicle treated mice in paclitaxel-treated mice. In contrast, 
axonal levels of both α-tubulin and end-binding protein 1 (EB1) rapidly returned to control 
values at 14 day from initially induced levels at the end of the MTD treatment in both 
paclitaxel and eribulin treated mice.  In summary, we found that (i) morphologically, sciatic 
nerve axons recovered more rapidly from eribulin and ixabepilone-induced morphological 
and biochemical effects than did paclitaxel-treated mice, and (ii) biochemically, drug-
induced increases in protein expression levels following paclitaxel and eribulin treatment are 
relatively transient.  Taken together, our data in mice indicate a milder onset and faster 
recovery with eribulin and ixabepilone treatment than for paclitaxel. 
Finally, we made progress developing an in-vitro cell culture model for studying the 
cellular and molecular mechanisms that regulate neuron’s response to microtubule 
inhibition.  We found that all MTAs reduced neurite area of neuronal cells at concentrations 
that coincided with a possible shift in microtubule mass and a change in cytosolic α-tubulin 
acetylation.  When we compared the IC50 concentrations for neurite area and inhibition of 
cancer cell proliferation, we found that eribulin was far less potent to neurons than it was to 
cancer cells, indicating that neurons are more tolerant of eribulin’s action as compared to 
ixabpilone, paclitaxel, and vincristine. 
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Chapter 1: General Introduction 
Microtubules are essential for vital cell processes 
The microtubule cytoskeleton is so crucial to the cell that without it, eukaryotic life 
could not continue.  The very process of ensuring transfer of genetic material between 
dividing cells requires an intact and properly functioning microtubule cytoskeleton.  Among 
their many duties in cells, microtubules are involved in diverse and dynamic functions such 
as maintaining cell shape, vesicle trafficking, cellular transport, and mitosis. 
The highly dynamic behavior of microtubules allows the cell to rapidly respond to both 
intracellular and extracellular signaling.  Such signals influence cell shape, motility, and cell 
division.  In addition to providing physical structure and support for the cytoplasm, 
microtubules provide a vast network of conduits on which to transport cargoes from the 
protein-producing endoplasmic reticulum to the periphery of the cell.  These cargoes include 
vesicles containing membrane-bound channels and receptors, transcription factors or nucleic 
acid coding sequences, and organelles such as mitochondria.  If one desired to induce great 
inconvenience to a cell, interfering with its microtubules would be a fantastic strategy. 
 
Microtubule structure and dynamic instability 
Each microtubule is composed of repeating heterodimer subunits of closely homologous 
α and β-tubulin monomers.  These heterodimers bind in a head to tail fashion to form linear 
protofilaments.  Each protofilament is polarized, with the β-tubulin end facing outward (the 
plus end) and the α-tubulin end facing inward (minus end).  Once assembled, the 
microtubule resembles a hollow cylinder with a diameter of ~24nm and containing an 
average of 13 protofilaments (Akmanova and Steinmetz 2008).   
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Each microtubule is able to grow and shorten as needed depending on spatiotemporal 
requirements of the cell.  There are two important dynamic activities of microtubules: 
treadmilling and dynamic instability.  The first behavior involves net growth at one 
microtubule end and balanced net shortening at the opposite end, creating a retrograde flow 
of subunits from the plus end to the minus end.  The rate of treadmilling is determined by 
differences in the critical subunit concentrations at the opposite microtubule end (Margolis 
and Wilson 1978, Rodionov and Borisy 1997, Panda et al. 1999).  The second dynamic 
behavior of microtubules, called dynamic instability, is characterized by four main activites: 
growing, shortening, transitioning from the growth or paused state to shortening, or 
transitioning from shortening to growth or pausing.  To accomplish these complex 
polymerization dynamics, αβ-tubulin cycles between two distinct states: GTP- and GDP-
bound, with an intermediate conformation of GDP+Pi existing between these two states.  A 
long-standing model for how αβ-tubulin associated with GTP make it more microtubule 
compatible stated that GTP induces a more straight conformation of the heterodimer that 
lowers the energy of polymerization (Mandelkow et al. 1991, Melki et al. 1989, Alushin 
2014).  A generally accepted model states that the bent unpolymerized αβ-tubulin monomer 
is straightened upon binding GTP.  Thus, the growing plus end of a microtubule is protected 
from depolymerization by a GTP cap of αβ-tubulin bound to GTP.  Following incorporation 
into the lattice, each dimer then hydrolyzes its bound GTP to GDP.  The GDP-bound 
conformation becomes strained, but remains polymerized due to stabilizing interactions 
within the surrounding heterodimer lattice.  If the pace of GTP hydrolysis exceeds that of 
subunit addition, a depolymerizing event called a catastrophe occurs causing the microtubule 
end to rapidly lose subunits in a peeling fashion.  Following this rapid depolymerization, 
new subunits can again be added to re-initiate the process the assembly, a process known as 
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a rescue.  This switching between alternating phases of growth and disassembly allows 
individual microtubules to sample cellular regions and retract in cases where they do not 
encounter a stabilizing environment or their protein targets, such as kinetochores during 
mitosis. 
 
Regulation of microtubule dynamics 
The coordinated regulation of microtubule function and assembly, a process thought to 
be closely regulated and reflecting integration of various extracellular signals, requires very 
tight regulation of MT dynamics.  Considering the importance of microtubules to normal cell 
functions, it is not surprising that cells have evolved robust strategies for properly regulating 
their microtubules using multiple molecular mechanisms, including altered tubulin isotype 
expression patterns, post-translational modifications and the action of a number of  
microtubule associated proteins (MAPs).  Alone or in combination these mechanisms can 
provide highly tunable regulatory power (Bhattacharya et al. 2011; Janke and Bulinski 2011; 
Lu and Luduena 1993; Savage et al. 1989; Song and Brady 2015).  The highly dynamic 
nature of microtubules can be modified to suit the different requirements of different cellular 
compartments, for example, in the cell body versus the distal axon of a neuron. 
Dynamic instability is also tied to cellular metabolism via intracellular levels of GTP, as 
well as by the concentration of available tubulin subunits.  The amount of total tubulin 
protein in the cells is regulated through a negative auto-feedback loop, where non-
polymerized tubulin protein subunits bind and specifically inactivate tubulin mRNA.  This 
occurs when the concentration of tubulin subunits is elevated. On the other and, when 
tubulin protein subunit levels decrease, the feedback loop is not active and tubulin 
translation proceeds to restore the desired balance (Gay et al. 1987; Pachter et al. 1987).  
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The binding of microtubule associated proteins (MAPs) can directly influence MT 
dynamics as well as serve as scaffolds for the binding of additional proteins.  For example, 
microtubule end binding proteins EB1 (end binding protein 1) and EB3 (end binding protein 
3) bind selectively to the growing plus ends of microtubules, facilitating MT polymerization, 
directional cues, and cross-links to actin filaments (Akhmanova and Steinmetz 2015; Maurer 
et al. 2012).  EB1 has been implicated in promoting microtubule growth and axonal 
transport while EB3 can serve as a linker between dynamic microtubules and the actin 
cytoskeleton (Geraldo et al. 2008; Gu et al. 2006; Jaworski et al. 2009). 
The post-translational modifications of tubulin are so diverse that they rival histone 
modifications in the nucleus, leading some to call it a tubulin code (Janke 2014).  While the 
functions of many tubulin modifications are unknown, some modifications have been shown 
to regulate the dynamicity and stability of the microtubule lattice (Janke and Bulinski 2011).  
The C-terminal tail of tubulin is the most well-known site of modification.  This 
unstructured polypeptide chain is exposed on the outer face of the microtubule and is subject 
to many potential modifications including glycosylation, glutamylation, detyrosination, and 
polyamylation (Janke and Kneussel 2010).  These modifications can in turn influence the 
ability of proteins to interact with the microtubule, such as motor proteins (Reed et al. 2006).  
While the majority of regulatory sites are located at the outer face of the microtubule 
cylinder or at tubulin’s C-terminal tail, another regulatory site is found in the lumen.  
Acetylation of -tubulin's lysine40, via the tubulin acetyltransferase (αTAT) is correlated 
with long-lived and stable microtubules (Palazzo et al. 2003, Hubbert et al., 2002; 
Matsuyama et al. 2002).  The ability to acetylate and deacetylate microtubules provides a 
tunable mechanism for regulating dynamic instability.  Interestingly, the presence of αTAT, 
and not the sole presence of the acetyl group, seems to be necessary for the additional 
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stability of microtubules assembled in-vitro (Haggarty et al. 2003).  The current model states 
that the small αTAT enzyme diffuses into the lumen through the terminal pore and slowly 
catalyzes the addition of acetyl groups to α-tubulin at lysine-40 (Soppina et al. 2012, Syzk et 
al. 2016).  Remaining bound to the lumen, αTAT stabilizes the lattice from the lumen.  The 
reverse reaction of deacetylation is performed primarily by a histone-deacetylase HDAC6, 
with functional redundancy provided by other HDAC family members (Dompierre et al. 
2007). 
One hypothesis for the structural effects of tubulin acetylation suggests that an inter-
protofilament salt bridge is responsible for regulating the interactions between 
protofilaments and thus may regulate protofilament number (Cueva et al. 2012).  
Interestingly, electron micrographs do not indicate any gross structural changes to the 
microtubule itself compared to non-acetylated microtubules.  It remains to be confirmed 
whether acetylation endows stability or rather accumulates on low-turnover tubulin subunits 
that have been stabilized in other ways. Nonetheless, tubulin acetylation has cellular 
consequences. For example, multiple lines of evidence indicate that acetylation improves the 
affinity and processivity of kinesin-based molecular transport (Konishi and Setou, 2009; 
Reed et al., 2006). 
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Mechanism of Action of Microtubule Targeting Agents I: Anti-cancer efficacy, Binding 
Sites and Effects on Microtubules 
The anti-cancer activity of microtubule targeting drugs is widely believed to derive 
from their ability to alter normal regulatory mechanisms controlling microtubule dynamics.  
Rapidly dividing cells such as cancer cells are especially dependent on the MT network and 
are therefore more sensitive to drug induced changes in MT dynamics (Jordan and Wilson 
2004).  It is generally accepted that microtubule targeting agents (MTAs) combat tumor 
growth by altering the growing and shortening dynamics of microtubules that are essential 
for cells to undergo chromosome segregation and mitosis (Giannakakou et al. 2002; Jordan 
and Wilson 2004).  Cells rely heavily on properly functioning MTs during mitosis to form 
spindles that organize and allocate genetic material to their progeny by binding to 
kinetochores.   Disruption of these essential functions lead to deleterious effects and cell 
death through apoptosis (Argyriou et al. 2012; Fehrenbacher 2015; Field et al. 2014; Jordan 
and Wilson 2004; Poruchynsky et al. 2015). 
While all MTAs target microtubules, various MTAs differ greatly in their 
mechanisms of microtubule binding and their effects upon microtubule dynamics.  There are 
two main classes of microtubule targeting drugs that are grouped according to their effects 
on microtubules: 1) compounds that shift the equilibrium toward polymerized microtubules 
and 2) compounds that shift the equilibrium toward soluble tubulin subunits.  Both 
mechanisms of action result in apoptosis and are effective in reducing the growth of various 
types of cancers.  Paclitaxel, a first-line agent of the taxane class, binds along the inner 
surface of the entire microtubule length to a binding site in the β-subunit, but not to soluble 
tubulin, to promote stabilization and net microtubule polymerization that is driven in large 
part by suppression of shortening events (Jordan 1993 et al., Derry et al. 1995, Parness and 
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Horwitz 1981; Nogales et al., 1995).  Similarly, ixabepilone (an epothilone) stabilizes the 
microtubule lattice and thus results in an excess of microtubule polymer leading to an 
inability of the cell to complete mitosis.  In contrast, eribulin (a halichondrin) binds only at 
the plus (+) ends of microtubules and to free tubulin subunits, promotes microtubule 
dynamic instability and net microtubule depolymerization (Jordan et al., 2005; Smith et al., 
2010; Bai et al.,2011).  Another molecule in the class of destabilizing drugs, vincristine (a 
vinca alkaloid) binds to tubulin and microtubules and promotes depolymerization and 
destruction of mitotic spindles.  Importantly, the most important effects of these agents (anti-
mitotic) are based on their ability to suppress spindle-microtubule dynamics and not by 
changing microtubule polymer mass.  Drugs that increase or decrease microtubule 
polymerization at high concentrations suppress dynamics at 10-100 fold lower 
concentrations.  Thus it simplifies the story to consider MTAs as either polymerizing or 
depolymerizing however it seems to be their chemotherapeutic effects on dynamics that 
mitotically blocks cells and initiates apoptosis (Jordan and Wilson 2004).  
 
Nociception and susceptibility of peripheral nerves 
The peripheral nervous system has evolved to detect and transmit environmental stimuli 
to the central nervous system.  As such, many of the neurons in the peripheral nervous 
system (PNS) have taken on extremely elongated morphologies.  Indeed, many of the nerve 
cells of the PNS are among the longest cells in the human body.  For the axons of sensory 
neurons innervating the hands and feet, cells send processes from their cell bodies just 
outside the spinal cord to the periphery.  Their axons are contained in tightly packed bundles 
that eventually terminate at muscle tissue, in encapuslated endings (such as Meisner’s or 
Pacinian corpuscles), or in free, unencapsulated endings.  Each bundle is organized and 
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protected by Schwann cells, which may or may not myelinate the axons contained within the 
bundle.  There are two major classes of neurons: the fast, large myelinated Aδ fibers which 
are responsible for perception of intense mechanical and thermal stimuli, and the slow, 
smaller unmyelinated C fibers which transmit thermal, mechanical, and chemical 
information (Woolf 2007).  Thin, unmyelinated axons are organized into Remak bundles 
protected by a single Schwann cell.  The cell bodies, or soma, of the long sensory axons of 
the sciatic nerve are organized in the dorsal root ganglia (DRG), positioned just outside of 
the spinal cord in the dorsal horn.  The speed of electrochemical transmission is directly 
proportional to the diameter and degree of myelination.  Fast myelinated Aδ fibers transmit 
action potentials at 5-30 m/s and respond to intense mechanical and thermal stimuli while 
the smaller unmyelinated C fibers respond at 2 m/s and respond to thermal, mechanical, and 
chemical stimuli (referred to as “polymodal”). 
Although the axonal and somal compartments are of the same cells, the long axons and 
cell bodies are highly specialized and distinct from one another in their structure and 
function. For example, axonal microtubules are more stable/less dynamic than cell body 
microtubules (Janke 2014; Song and Brady 2015). Therefore, it is reasonable to hypothesize 
that somal and axonal microtubules may respond differently to stress and stimuli (e.g., 
chemotherapeutic assault). 
The neural process of encoding and processing noxious stimuli, termed nociception, is 
transmitted through specialized sensory nerve fibers called nociceptors.  Noxious stimuli are 
damaging or potentially damaging stimuli including extremes of temperature, mechanical 
stimulation, and allogens that provoke an avoidance response. A nociceptor is thus a 
peripherally localized neuron preferentially sensitive to a noxious stimulus. Peripheral 
nociceptive axons arise from DRGs and terminate in free endings in peripheral tissues that 
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contain a diverse repertoire of receptors.  These excitatory neurons release glutamate as their 
primary neurotransmitter and are generally electrically silent.  They transmit an all or none 
action potentials when stimulated by noxious stimuli to produce a pain response that 
responds to the frequency of action potentials. 
Schwann cells are resident microglia of the peripheral nervous system 
Schwann cells are intimately involved with peripheral axons.  They provide the 
myelin insulation required for signal propagation, trophic support, and even take on immune 
function in response to nerve injury.  Schwann cells are required for peripheral nerve 
regeneration and together with macrophages, are responsible for the clearance of molecular 
debris following injury (Lutz and Barres 2014).  Upon nerve injury, Schwann cells undergo 
transformations that include de-differentiation, proliferation, and subsequent re-
differentiation to establish a pro-regenerative environment for axons (Rosenberg et al 2012). 
 
Specialized function of microtubules in neurons 
After development, neurons no longer undergo cell division.  Their long processes are 
specialized to transmit electrical impulses from the periphery of an organism into the central 
processing centers such as the spinal cord and brain.  Some cells must be extremely long to 
cover the great distances required between input locations and the CNS.  In some peripheral 
nerve fibers, the distance from the nucleus to distal end of the axon can be longer than 1m!  
This is an enormous distance over which to maintain homeostasis, as the soma of each cell is 
the protein-producing center and needs to package and translocate newly synthesized 
proteins to the distal tips.  Each nerve ending and synapse is rich with a variety of channels 
and receptors that detect many different stimuli from the environment (Julius and Basbaum 
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2001).  The different requirements of microtubules in different neuronal compartments 
dictates that they need to behave differently.  Indeed, the post-translational modifications of 
microtubules in axons differ from those in cytoplasmic microtubules (Janke and Kneussel 
2010).  In neurons, the axon must be maintained as a semi-permanent structure, and 
microtubules are one of the primary components of the axonal cytoskeleton.  Axonal MTs 
must establish and maintain a stable microtubule lattice to provide intact structure and 
transport capabilities to and from the soma. 
 
Transport of cargo along microtubule networks  
The polarity of microtubules allows directional movement of motor proteins in a 
retrograde direction towards the soma or anterograde direction toward the distal synapse.  
Different motor proteins exhibit a preference for directional travel along microtubule 
networks: dynein transports retrograde cargo while the kinesin family of proteins directs 
anterograde cargo (Morfini et al. 2011) 
Neurons require vast amounts of energy to repolarize their membranes after 
depolarization.  This energy requirement means that mitochondria must constantly be 
supplied from the nucleus to the distal ends of the axon to maintain proper resting membrane 
potentials.  Among the many cargoes that rely on microtubules for transport, mitochondria 
are one of the most abundantly transported organelles along the microtubule cytoskeleton in 
neurons (Millecamps and Julien 2013).  These ATP-producing machines are targeted for 
release from microtubules at nodes of Ranvier where channels are clustered (Pareyson et al. 
2015, Saxton and Hollenbeck 2012). 
In addition, many proteins synthesized in the ER are loaded onto microtubules in 
vesicles and shipped to distal processes.  These proteins include synaptic proteins, channels, 
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cytoskeletal subunits, and microtubule associated proteins.  Interestingly, a small amount of 
mRNA bound to ZBP (zip-code-binding) proteins is also loaded onto kinesins for 
anterograde trafficking, which supports the hypothesis of local protein translation in distal 
axons (Yoo et al. 2013, Merianda et al. 2013). 
Retrograde trafficking along microtubules is primarily driven by minus-end directed 
dynein motors.  The various retrograde cargoes include survival factors (NGF/TrkA), 
lysosomes (containing proteins to be degraded), damaged mitochondria, and injury response 
signals (Morfini 2011).  When the injury response is activated in the distal axon, retrograde 
signaling results in altered gene expression in the nucleus (Watkins et al. 2013).  One 
example is the JNK-interacting proteins that are found at the JNK-interacting family of 
linkage proteins (JIPs) that interface cargo with motor protein domains.  When JNK is 
activated via phosphorylation, it in turn activates the transcription factor c-Jun via 
phosphorylation to induce an injury response.  Genes activated by this transcription factor 
include both degenerative and pro-regenerative proteins, which prepare the neuron for both 
programmed axon degeneration and subsequent regrowth (Tedeschi and Bradke 2013). 
 
Chemotherapy Induced Peripheral Neuropathy 
Microtubule-targeting chemotherapy drugs have been among the most successful 
treatments in slowing the progression of many different types of cancers over recent decades.  
However, their ability to control rapidly proliferating cancer cells continues to be marred by 
the induction of severe dose-limiting side effects.  MTAs are generally delivered to patients 
systemically, exposing both tumor and non-tumor tissues to the chemical assault, which can 
lead to serious side effects including chemotherapy-induced peripheral neuropathy (CIPN) 
(Argyriou et al. 2012; Argyriou et al. 2014; Carlson and Ocean 2011; Grisold et al. 2012).  
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For example, the untargeted systemic injection of these potent anti-neoplastics exposes the 
microtubule-rich axons of the peripheral nervous system to their effects.   
CIPN impedes favorable clinical outcomes and represents a major obstacle to 
chemotherapy due to the frequency of dose reductions and elective treatment cessations.  
This debilitating sensory neurotoxicity of the limb extremities often results in attenuation of 
dosage, up to complete cessation of chemotherapy, such that very aggressive cancers cannot 
be adequately controlled (Argryiou et al. 2012).  Traditional pain management strategies 
such as analgesics, anti-inflammatories, and opioids have had negligible success in reducing 
chronic neuropathic pain. Part of the challenge in developing effective treatments for 
managing neuropathy during chemotherapy is that the underlying cellular mechanisms of 
chemotherapy-induced peripheral neuropathy are currently undefined. 
A number of clinically based scales are available for grading of the severity of CIPN, 
which are based upon the extent of disruption of daily living activities.  Although none has 
achieved universal acceptance, the National Cancer Institute’s Common Terminology 
Criteria for Adverse Events (NCI-CTCAE) is one of the most commonly used scales.  It 
ranges from grade 1, representing asymptomatic effects, to grade 4 representing severe 
disruption in activities of daily living and life-threatening consequences requiring immediate 
intervention (Carlson and Ocean 2011, Argyriou et al. 2014; Fehrenbacher 2015).  Currently 
there is no efficacious therapy for peripheral neuropathy besides dosage reduction, leading to 
poorer patient outcomes (Jaggi and Singh 2012).  Traditional pain management strategies 
including analgesics and anesthetics have been largely unsuccessful (Argyriou et al. 2012).  
A clinician’s ability to treat aggressive cancers is dependent on the management of this dose-
limiting condition, and improved chemotherapy will result from more effective control of 
neuropathy.  
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For patients receiving microtubule targeting agents, approximately 30–40% will 
experience severe CIPN symptoms that are largely sensory in nature.  The described pain 
includes hypersensitivity to pressure and hot or cold temperatures, tingling, burning 
sensations, numbness, and/or a loss of deep tendon reflexes. Symptoms can occur shortly 
after the first dose of some MTAs, and are closely correlated dosage: either single or 
cumulative (Argyriou et al. 2008).  These symptoms often begin in the distal extremities 
(i.e., fingertips and toes) and progress proximally up the arms and legs, suggesting that the 
longest nerves are most vulnerable (Argyriou et al. 2012; Carlson and Ocean 2011; 
Fehrenbacher 2015; Grisold et al. 2012; Windebank and Grisold 2008). 
Most clinical investigations on the incidence and severity of neuropathy during 
treatment are compounded by the reality that patients often receive different doses on 
different schedules.  In clinical practice patients are also often treated with combinations of 
drugs that are individually known to cause CIPN and then receive sequential treatments for 
recurring cancers with additional CIPN-inducing drugs.  For example, paclitaxel is indicated 
as a first line therapy for many types of cancers.  If a patient becomes resistant to paclitaxel 
then usually an epothilone regimen, such as ixabepilone (a second line defense) is begun.  If 
the patient’s cancer continues to elude epothilone treatment, a third line defense is needed 
such as eribulin.  Thus the difficulty in comparing the incidence of neuropathy for 
ixabepilone and paclitaxel is that patients will likely already have pre-existing neuropathy 
from prior paclitaxel treatment when they receive additional or combinatorial therapies. 
 
Incidence, Progression, and Reversibility of Clinical CIPN Symptoms 
The onset, rate of progression, severity and reversibility of CIPN symptoms vary 
greatly among different MTA treatments (Argyriou et al. 2012; Carlson and Ocean 2011; 
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Windebank and Grisold 2008).  The incidence and severity of MTA-induced neuropathy 
depend on many factors such as the agent used, cumulative dose, dose intensity, treatment 
schedule, duration of infusion, pervious chemotherapy regimens, and agents used in 
combination (Lee and Swain 2006).  The following section summarizes the distinct 
characteristics for each of four commonly used microtubule-targeting agents.  The diversity 
of these agents in their rates of onset, progression, and recovery allows correlative 
relationships of their cellular and molecular effects to be identified so that the underlying 
molecular mechanisms can be better understood. 
 
Paclitaxel 
Paclitaxel neuropathy is primarily sensory in nature and includes painful numbness, 
decreased vibration sensitivity, and loss of deep tendon reflex (Lipton et al. 1989, 
Stubblefield et al. 2009). The incidence of severe neuropathy (grades ¾) ranges from 2-32% 
at doses from 100-300 mg/m
2 
over a 3 hour infusion
 
period (Gradishar et al. 2005, Jones et 
al. 2005, Seidman 1995).  Patients treated with paclitaxel tend to exhibit a higher frequency 
of severe CIPN than do patients treated with eribulin (Carlson and Ocean 2011, Windebank 
and Ocean 2011, Argyriou et al. 2012; Gradishar et al. 2011). Generally, symptoms of 
taxane-induced CIPN improve or resolve within the first 3–6 months after the 
discontinuation of treatment (Grisold et al. 2012).  While 50% of patients treated with 
paclitaxel recovered within 9 months, symptoms persisted in 41% of patients at 3 years, 
suggesting that neurotoxicity can persist long-term (Pace et al. 2007).  After a median follow 
up of 23.5 months, 40.9% of patients showed persistent PIPN (de la Morena Barrio et al. 
2015). 
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Ixabepilone 
Ixabepilone is indicated for the treatment of breast cancer after taxane failure and is 
primarily sensory with painful numbness and burning in the extremities similar to paclitaxel.  
The incidence of severe neuropathy ranges from 12-20% at doses of 40-120 mg/m
2
 (Roche 
et al. 2007, Steinberg et al. 2008, Thomas et al. 2007).  In a study comparing neuropathy 
induced by eribulin and ixabepilone, the median time to onset for ixabepilone was 2.7 
months from the start of treatment (Vahdat et al. 2013).  The median and maximum times to 
resolution of ixabepilone neuropathy were 1.2 and 2.3 months, respectively (Perez et al. 
2007, Vahdat et al. 2013).  Interestingly, the reversibility of neuropathy after dosage 
intervention appears to be more rapid with ixabepilone than with taxanes (Swain and Arezzo 
2008). 
 
Vincristine 
Out of all the agents described here, vincristine induces the highest levels of severe 
neuropathy and is associated with a severe mixed sensory/motor polyneuropathy.  Grades ¾ 
neuropathy present at the relatively low dose of 2 mg/m
2  
(Sarris et al.2000).  Vinorelbine, 
another vinca alkaloid, requires higher doses of 25-30 mg/m
2
 to induce severe neuropathy in 
about 6% of patients and presents symptoms within the first 3 months (Vogel et al. 1999).  
While symptoms are usually reversible within 2 months after dosing, a long-term follow up 
of vincristine-treated patients revealed that 32% had mild but persistent sensory symptoms 
34 months after the end of treatment (Postma et al. 1993). 
 
Eribulin 
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Eribulin is a more recently approved third line therapy for metastatic breast cancer 
therapy for patients who had previously received at least two prior chemotherapy regimens, 
including an anthracycline and a taxane.  Eribulin has a more favorable safety profile and is 
normally provided at low doses similar to vincristine at 1.4 mg/m
2
, over a much faster 
infusion time of 3-5 minutes due to its improved solubility (Vahdat et al. 2013).  Eribulin is 
associated with the lowest incidence of neuropathy of the agents described here, from 3-8% 
experiencing severe neuropathy (Puhalla and Brufsky 2008, Cortes et al. 2011). Compared to 
paclitaxel, the median time to clinical onset of eribulin-induced neuropathy is more delayed 
at 8.3 months from the start of treatment.  However, symptoms resolve more quickly at a 
median time to total resolution of 1.8 months and lasting up to 11 months from the last dose 
only in rare cases (Vahdat et al. 2013).  Thus eribulin produces more mild, later onset, and 
more quickly resolving neuropathy in patients compared to paclitaxel, ixabepilone, and 
vincristine. 
 
Effects of MTAs on peripheral nerve morphology and function 
The free endings of nociceptors contain many specialized receptors such as the 
transient receptor potential (TRP) family of ion channels (Woolf and Ma 2007). Spinal 
administration of antisense oligonucleotides to the TRP family member TRPV4 abolished 
taxol-induced mechanical hyperalgesia in a rat model of peripheral neuropathy (Alessandri-
Haber et al. 2004).  A current debate in the field is whether preferential degeneration of 
either Aδ  or C fibers play a role in CIPN.  There is building evidence that taxol-induced 
sensory disturbance is characterized by preferential impairment of myelinated Aδ fiber 
function (Dougherty et al. 2004, Flatters et al. 2006).  Spontaneous discharge by both fibers 
has been reported in response to paclitaxel and vincristine (Xiao and Bennet 2008).  Skin 
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biopsies of human patients treated with either vincristine or paclitaxel showed deficiencies 
in mechanoreceptors and intraepidermal nerve fiber densities in the reported painful tissues 
(Boyette-Davis et al. 2011).  In a recent study comparing the effects of paclitaxel, 
ixabepilone, and eribulin on peripheral mouse tail nerves, our collaborators found a 
significant decrease in nerve conduction velocity (NCV) and nerve conduction amplitude 
(NCA) following paclitaxel and ixabepilone treatment at their maximum tolerated doses for 
two weeks.  Severe degenerative pathologic changes in morphology such as cytoplasmic 
inclusions, clear vacuolations, and swelling phenomenon have also been observed (Tanner et 
al. 1998). Eribulin, which causes less neuropathy in humans, did not induce significant NCV 
or NCA deficits and caused milder morphological changes in the sciatic nerve, indicating 
that peripheral neuropathy in mice correlates with electrical and morphological evidence of 
axon degeneration (Wozniak et al. 2011). The effects observed by these drugs in both skin 
biopsies and peripheral nerve electrophysiology point to axonal loss as an underlying 
mechanism for chemotherapy induced peripheral neuropathy.  Understanding the molecular 
events leading to these electrophysiological and patholigcal effects is the central motivation 
for the work described in this thesis. 
 
Models of CIPN 
Animal models have proven useful to investigate how chemotherapies differ in their 
patterns of producing neuropathy, axonopathy and myelinopathy (Han et al. 2013).  The 
maximum tolerated dose model is a commonly used animal model that involves establishing 
a maximum tolerated dose for each agent that is characterized by the loss of 20% of the 
animal’s body weight.  The MTD was defined as the highest dose level at which no more 
than 10% deaths occurred and/or at which no mice displayed more than 20% individual 
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weight loss and/or overt clinical signs of distress and/or inability to eat and drink, thus 
requiring euthanasia.  Mice treated at their MTD’s display reproducible dose-dependent 
reductions in caudal and digital nerve conduction velocities and amplitudes (Wozniak et al. 
2011) 
 
Relative Uptake and retention of each drug 
MTAs penetrate peripheral nervous tissue at vastly different rates.  Recent 
pharmacokinetic studies demonstrated that the tissue penetration index of the sciatic nerve 
for eribulin is 30 times that of paclitaxel (0.6 vs 0.02) (Wozniak et al. 2016).  In contrast to 
their rapid clearance from plasma, both drugs were retained in sciatic nerve and DRG tissue.  
While plasma concentrations were undetectable at 24 hours following the last dose of 2-
week MTD schedule, concentrations of paclitaxel and eribulin were maintained in sciatic 
nerve and DRG tissues for up to 26 days after the completion of dosing.  Paclitaxel exposure 
reached maximal levels in the DRG after the first dose, while in the sciatic nerve there was 
accumulation with multiple doses.  In contrast, eribulin exposure showed increasing 
accumulation in both DRG and sciatic nerve with multiple administrations (Wozniak et al. 
2016). 
 
Clinical considerations  
The demonstration that eribulin induces less frequent severe CIPN than the widely used 
paclitaxel raises the question of its relative anti-cancer efficacy relative to paclitaxel. A 
lower incidence of severe peripheral neuropathy would be most meaningful if it were 
coupled with equal or greater anti-cancer efficacy. Unfortunately, to date there have been no 
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clinical studies directly comparing the anti-cancer efficacies of eribulin and paclitaxel in the 
clinical setting. That said, eribulin was FDA approved in 2010 as a third line therapy for 
patients with metastatic breast cancer who had previously received at least two prior 
chemotherapy regimens, including an anthracycline and a taxane. At the time of the pivotal 
Phase III EMBRACE trial which led to the FDA approval, there was no standard of care for 
third line metastatic breast cancer, so EMBRACE was designed, in conjunction with the 
FDA, as a two-arm study of eribulin monotherapy versus “treatment of physician’s choice” 
(TPC), essentially capturing the individual judgments of hundreds of oncologists’ decisions 
as to the best personalized treatment of their specific patients (Cortes et al. 2012). 
EMBRACE stipulated that enrolled patients must have progressed within 6 months or less of 
the latest chemotherapy (Cortes et al. 2012). As such, the statistically significant 24 % 
increase in median overall survival between the two groups (13.1 months vs. 10.6 months 
for eribulin versus TPC, respectively) indicates that many patients exhibited prolonged 
survival on the eribulin arm despite the fact that they had previously progressed on taxane-
containing therapies. In addition, the preclinical work of Towle et al. (2001), demonstrated 
that eribulin is more effective at considerably lower doses than paclitaxel (at empirically 
determined MTD levels) in four different human tumor xenograft growth models in mice: 
potency differentials for eribulin versus paclitaxel based on complete tumor suppression 
ranged from 20- to 100-fold for different human tumors. Additionally, in these in vivo 
studies, eribulin consistently showed a wider therapeutic window compared to paclitaxel. 
Finally, eribulin showed an average 4.1-fold increased potency compared to paclitaxel on a 
molar basis in a library of eight human cancer cell lines, with ratios in the individual lines 
ranging from 2.0-fold to 27.8-fold.  Thus, although no direct head-to-head comparisons of 
eribulin versus paclitaxel have been conducted, existing clinical evidence from the 
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EMBRACE Phase III clinical trial pointing to eribulin activity after progression on taxanes, 
coupled with consistent preclinical evidence of greater potency both in cancer cell lines and 
human tumor xenograft models, raise the possibility that eribulin is either an equipotent or 
more potent anti-cancer agent relative to paclitaxel. In this context, the apparently lower 
neuropathic effects of eribulin relative to paclitaxel in both the clinic and laboratory settings 
can be viewed as not simply a consequence of lower overall potency, but rather a bona fide 
reduction in one of the most significant and troubling side effects of treatment with these 
two agents. 
 
Thesis Data 
The identification of molecular players involved in the onset and progression of 
CIPN will allow for new strategies to block or prevent neurodegeneration in peripheral 
neuropathy and other neurological diseases.  Since the timing of cancer treatment is known, 
a neuroprotective companion therapy for prevention of neuropathy would have great 
potential to minimize this toxic side effect. However, our knowledge of the underlying 
physiological mechanisms responsible for the induction of peripheral neuropathy by MT-
targeting drugs remains surprisingly limited. 
The overall goal of the experimental work undertaken in this thesis is to elucidate the 
cellular and molecular mechanisms of chemotherapy induced peripheral neuropathy.  This 
project began with correlative work in an MTD mouse model to investigate the onset and 
recovery from morphological and biochemical effects that occur in peripheral nerves upon 
treatment with MTAs.  We found that paclitaxel induced markedly more deleterious effects 
upon sciatic nerve morphology, such as nerve fiber loss and signs of axon degeneration (for 
example, solid circular regions of myelin signal lacking a phosphoneurofilament signal), 
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relative to the effects of eribulin (Benbow 2016). Additionally, eribulin had more potent 
positive effects upon microtubule biochemistry, creating an environment consistent with 
increased microtubule stabilization and growth.  These findings led us to hypothesize that 
long-term treatment with eribulin generates a more functional microtubule cytoskeleton than 
does similar treatment with paclitaxel, accounting at least in part for the reduced levels of 
severe CIPN observed with eribulin-treated versus paclitaxel-treated patients. 
To expand this work, we then examined the recovery from these initial effects over 
the course of six months.  We found that (i) morphologically, sciatic nerve axons recover 
more rapidly in eribulin treated animals than in paclitaxel treated animals and (ii) 
biochemically, drug-induced increases in protein expression levels following paclitaxel and 
eribulin treatment are relatively transient.  Interestingly, the effects of ixabepilone were mild 
compared to paclitaxel and eribulin despite its propensity for neuropathy in patients.  Taken 
together, our data in mice indicate a milder onset and faster recovery with eribulin and 
ixabepilone treatment than for paclitaxel. 
Finally, we developed an in-vitro cell culture model for studying the cellular and 
molecular mechanisms that regulate the cell’s response to microtubule inhibition.  We found 
that all agents reduced neurite area of neuronal cells at concentrations that coincided with a 
possible shift in microtubule mass and cytosolic α-tubulin acetylation.  When the drug 
concentration that induced a 50% reduction in neurite area was compared to the 
concentrations that inhibit cancer cell proliferation, eribulin was different in that it was far 
less potent to neurons than it was in inhibiting cancer cell growth, indicating that neurons are 
more tolerant of eribulin’s action as compared to ixabpilone, paclitaxel, and vincristine. 
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Chapter 1 Figures: 
1.1 Binding characteristics of common microtubule targeting agents  
1.2 Mechanism of action of various MTAs 
1.3 Incidence of Severe Neuropathy and Relevant Dosages of MTAs 
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Figure 1. Binding characteristics of common microtubule targeting agents of the vinca 
family (left), taxane and epothilone families (middle), and halichondrins (right).  Adapted 
from Jordan and Wilson 2004. 
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Figure 2. Examples of the mechanism of action of microtubule targeting agents.  The 
mechanism of action of eriblin (destabilizes microtubules) and paclitaxel (stabilizes 
microtubules) are shown.  Adapted from Kavallaris 2010. 
Destabilizing Stabilizing 
Eribulin Paclitaxel 
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Table 1. Incidence of Severe Neuropathy and Relevant Dosages of MTAs 
Drug 
 Incidence of Grade 3/4 
Neuropathy (% of patients) 
 Patient dose per 
cycle (mg/m2) 
Maximum 
tolerated dose in 
mice (mg/kg)§     
Eribulin 
 
7.8* 
 
1.4 1.25 
Vincristine 
 
31* 
 
2 0.85 
Paclitaxel 
 
2-32* 
 
100-300 30 
Ixabepilone   12-24**   40-120 3 
      * Carlson and Ocean. Clin Breast Cancer. 2011; 11, 2: 73-81 
 ** Gradishar, Curr Onc Rep. 2011; 13: 11-16 
  § Q2D3 dosing schedule, defined by 20% reduction in body weight 
ND = not determined  
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Chapter II. Effects of Paclitaxel and Eribulin in Mouse Sciatic Nerve: A Microtubule 
Based Rationale for the Differential Induction of Chemotherapy-Induced Peripheral 
Neuropathy 
 
Summary 
Microtubule targeting agents (MTAs) often lead to treatment limiting and life threatening 
side effects, including chemotherapy-induced peripheral neuropathy (CIPN). The frequency 
of severe CIPN varies among different MTAs. Since the microtubule binding interactions 
and mechanisms of action also vary among MTAs, we hypothesized that these distinct 
mechanisms may underlie the variability in frequency of severe CIPN. Using a two-week, 
maximum tolerated dose model, we morphologically and biochemically analyzed sciatic 
nerves from mice treated with either paclitaxel or eribulin. These drugs differ in their 
manner of microtubule binding and mechanisms of action and reports indicate paclitaxel 
also induces a higher frequency of severe CIPN than does eribulin. Morphologically, 
paclitaxel increased the frequency of observed signs of axon degeneration more significantly 
than did eribulin. Alternatively, eribulin but not paclitaxel induced occasional myelin “halo” 
structures. Biochemically, paclitaxel, and eribulin both induced α-tubulin expression (~1.9- 
and ~2.5-fold, respectively) and tubulin acetylation, a marker for microtubule stability, (~5- 
and ~11.7-fold, respectively). Eribulin but not paclitaxel-induced EB1 expression ~2.2-fold 
while paclitaxel but not eribulin mildly suppressed EB3 expression. Both EB proteins are 
associated with microtubule growth. Eribulin’s combination of relatively mild deleterious 
morphological effects coupled with more potent biochemical changes promoting 
microtubule stability and growth in mice correlate with lower frequencies of severe CIPN in 
humans. We suggest that these eribulin-induced effects create a relatively stable microtubule 
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network that compensates, in part, for the toxic anti-cancer effects of the drug, leading to 
fewer reported incidences of CIPN than for paclitaxel. 
 
Introduction 
 The anti-tumor activity of MTAs stems from their ability to alter normal regulatory 
mechanisms controlling microtubule dynamics and microtubule-based transport, which can 
in turn lead to tumor cell death (Argyriou et al. 2012; Field et al. 2014; Jordan and Wilson 
2004; Poruchynsky et al. 2015).  Unfortunately, MTAs also expose non-target tissues to 
chemical assault that can cause significant adverse side effects.  As the peripheral nervous 
system is highly susceptible to deleterious MTA-induced effects, chemotherapy-induced 
peripheral neuropathy (CIPN) is among the most frequent and serious side effects of MTA 
treatment. CIPN can cause symptoms ranging from numbness and tingling to 
hypersensitivity and severe neuropathic pain. These symptoms generally begin at the distal 
extremities, such as the fingertips and toes, and progress proximally toward the trunk, 
suggesting that the longest axons are the most vulnerable (Argyriou et al. 2012; Carlson and 
Ocean 2011; Windebank and Grisold 2008). These symptoms can become treatment 
limiting, and in some cases, even life threatening. The only strategies to address CIPN are to 
either reduce drug dosage or cease treatment altogether, both of which undermine attempts 
to control a patient’s cancer. Since MTAs are a major component of available clinical anti-
cancer strategies, CIPN can be a major obstacle to successful clinical anti-cancer efforts.  
          The severity, clinical presentation and reversibility of neuropathic symptoms can 
vary greatly between different MTA treatments (Argyriou et al. 2012; Argyriou et al. 2011; 
Carlson and Ocean 2011; Windebank and Grisold 2008). For example, paclitaxel treated 
patients generally exhibit a higher frequency of severe neuropathy than do eribulin treated 
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patients (Carlson and Ocean 2011; Gradishar 2011). Consistent with these observations, 
paclitaxel treatment of mice causes significant axon loss, morphological changes in myelin 
and reduction of nerve conduction velocity whereas eribulin treatment generated 
significantly milder morphological changes with no impairment of conduction velocity 
(Boehmerle et al. 2014; Wozniak et al. 2011). Importantly, different MTAs also differ 
greatly in their mechanisms of microtubule binding and their effects upon microtubule 
dynamics.  For example, the taxanes (e.g. paclitaxel) bind the inner surface along the entire 
length of microtubules, tend to stabilize microtubules and to promote net microtubule 
polymerization. These activities are driven, in large part, by suppression of microtubule 
shortening events (Derry et al. 1995). In contrast, eribulin (a halichondrin) binds only at the 
plus (+) ends of microtubules, promotes microtubule dynamic instability and promotes net 
microtubule depolymerization. These activities are driven, in large part, by binding to 
soluble tubulin and shifting the balance between soluble tubulin and microtubules, thus 
resulting in net loss of microtubule polymer (Jordan et al. 2005; Smith et al. 2010). Over the 
past two decades, it has become increasingly clear that the regulation of microtubule 
growing and shortening events is key to understanding microtubule action and the resulting 
cellular consequences, thereby providing a potential molecular link between MTA action 
and clinical observations. Taken together, these observations lead us to hypothesize that 
different patterns of CIPN induced by different MTAs are the result of their different 
underlying mechanisms of action. 
In addition to their important roles in dividing cells (i.e., cell division and transport), 
microtubules are also essential for many functions in post-mitotic mature neurons, including 
the maintenance of highly elongated neuronal morphologies and axonal transport, the rapid 
movement of cargo between neuronal cell bodies and distal axonal regions (Carlson and 
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Ocean 2011).   One often stated hypothesis for MTA-induced CIPN posits that the drugs 
interfere with normal microtubule-dependent axonal transport, which in turn initiates 
downstream biochemical and morphological neurodegeneration (Morfini et al. 2009). 
Consistent with this model, paclitaxel treatment can slow the rate of kinesin-driven 
anterograde transport more than eribulin treatment (Lapointe et al. 2013), in parallel with the 
relative neuropathic potencies of these two drugs. 
Cells possess numerous mechanisms to regulate microtubule dynamics. For example, 
tubulin subunits in relatively stable microtubules are often acetylated at lysine-40. While 
tubulin acetylation has historically been viewed as a marker but not a cause of microtubule 
stability, recent work suggests a more active role. For example, increasing tubulin 
acetylation can rescue dysfunctional axonal transport and locomotor deficits in Drosophila 
(Godena et al. 2014) and can promote recruitment of dynein and kinesin-1 to microtubules in 
vitro and in mammalian cells (Dompierre et al. 2007).  Additionally, microtubule dynamics 
can be influenced by a number of different microtubule-associated proteins (MAPs), 
including the end binding proteins EB1 and EB3. EB1 has been implicated in promoting 
microtubule growth and axonal transport while EB3 can serve as a link between dynamic 
microtubules and the actin cytoskeleton (Geraldo et al. 2008; Gu et al. 2006; Jaworski et al. 
2009).  We have previously proposed that proper function and viability of cells, including 
post-mitotic neurons, requires that cells actively maintain and regulate their microtubule 
dynamics within a window of tolerable activity levels (Bunker et al. 2004) – both overly 
dynamic and overly stable microtubules can lead to neuronal cell death.  
Here, we sought to compare cellular and molecular changes within mouse sciatic 
nerves following treatment with two different MTAs possessing different mechanisms of 
action and different probabilities of inducing severe CIPN. The goal was to correlate cellular 
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and molecular effects with the frequency of inducing severe CIPN. Specifically, we 
compared mice treated at their maximum tolerated dose (MTD) of either paclitaxel or 
eribulin with vehicle treated control mice. We found that paclitaxel induced markedly more 
deleterious effects upon sciatic nerve morphology, such as nerve fiber loss and signs of axon 
degeneration (for example, solid circular regions of myelin signal lacking a 
phosphoneurofilament signal), relative to the effects of eribulin. Additionally, eribulin had 
more potent positive effects upon microtubule biochemistry, creating an environment 
consistent with increased microtubule stabilization and growth. Taken together, we propose 
that eribulin treatment generates a more stable and functional microtubule network than that 
produced by paclitaxel treatment. This perspective provides a molecular rationale for the 
observation that eribulin induces less frequent CIPN than does paclitaxel in human patients. 
 
Materials and Methods 
Antibodies 
The following primary antibodies were used in immunohistochemical analyses:  anti-
α-tubulin (Millipore, 04-1117, 1:100 dilution (Zhang et al. 2011)),  anti-acetylated tubulin 
(Cell Signal, 5335, 1:800 dilution, (Creppe et al. 2009)), anti-EB1 (Millipore, AB6057, 
1:500 dilution, (Vitre et al. 2008)), anti-EB3 (Santa Cruz, SC-101475, 1:200 dilution, (Levy 
et al. 1994)), anti-myelin basic protein (Millipore, AB9348, 1:100 dilution, (Heller et al. 
2014), anti-phosphoneurofilament (Covance, SMI-31R, 1:2000 dilution, (Choi et al. 2008)). 
FITC, Cy3 and Cy5 conjugated secondary antibodies were purchased from Jackson 
ImmunoResearch and used at 1:200 dilution. 
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Drugs 
Eribulin mesylate (synthesized at Eisai Research Institute and stored at -80
o
 C in the 
dark) was dissolved in 100% anhydrous DMSO (Sigma-Aldrich) to produce a 10 mg/ml 
stock solution, which was aliquoted and stored at -80
o
 C until the day of administration. 
Each administration day, the stock solution was thawed and diluted with saline to a final 
concentration of 0.25 mg/mL in 2.5% DMSO/97.5% saline yielding dosing solutions in a 10 
mL/kg volume. Paclitaxel, (LC Laboratories, Woburn, MA; stored at -20
 o
 C in the dark) was 
dissolved in ethanol (100%) at 10% of final volume. An equal volume of cremophor (10% 
of final volume) was then added and the mixture re-vortexed for about 10 min. Immediately 
prior to injection, ice cold saline was added to final volume (as 80% of final), and the 
solution was maintained on ice during dosing. Dosing solutions were made fresh daily and 
dosed in a volume of 10 mL/kg. 
 
Animal Studies 
Female BALB/c mice (approximately 7–8 weeks old at onset of dosing) were 
obtained from Harlan Laboratories Inc. (Indianapolis, IN) and maintained with free access to 
water and a standardized synthetic diet (Harlan Teklab). Animal housing and procedure 
room temperature and humidity were maintained at 20 ± 2
o
 C and 55 ± 10%, respectively. 
Artificial lighting provided a 12 h light/12 h dark cycle (light 7 a.m.–7 p.m.).  All 
experimental protocols were approved by the Institutional Animal Care and Use Committee 
of Sobran Inc (Baltimore, MD) and adhered to all of the applicable institutional and 
governmental guidelines for the humane treatment of laboratory animals.  Mice were 
randomly assigned into vehicle, eribulin or paclitaxel treatment group (n= 5) 
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Drugs were administered 3 times a week (Monday, Wednesday, Friday) for 2 weeks into 
the caudal vein at a dose that was earlier determined to be MTD (Wozniak et al. 2011), 
specifically 30 mg/kg and 1.25 mg/kg for paclitaxel and eribulin, respectively.  Twenty-four 
hours after administration of the sixth and final dose, mice were deeply anesthetized with 
10% chloral hydrate and euthanized by transcardial perfusion with PBS followed by 4% 
paraformaldehyde in 0.1 mM phosphate buffer, pH 7.4, for 10–15 min.   Subsequently whole 
mid-thigh sections of sciatic nerve were dissected and placed in perfusion fixative at 4
o
C. 
 
Sectioning 
Fixed nerves were embedded in 10% agarose and cross-sectioned using a Leica 
VT1000S vibratome. 100μm slices were taken in the distal to proximal direction in 1X PBS 
at room temperature, then transferred to a 4% paraformaldehyde/PBS solution for storage at 
4
o 
C until staining. Approximately 0.75 cm of Sciatic nerve tissue was sectioned. 
 
Antibody Staining  
Sections were stained from both proximal and distal ends from a total approximate 
length of 0.75 cm of nerve.  Individual sections were stained with antibodies recognizing -
tubulin, acetylated tubulin , EB1 or EB3. All sections were also stained with anti-
phosphoneurofilament and anti-myelin basic protein as internal controls and in order to 
identify regions of interest (for example, neuronal cells).  Sections were incubated in PBT 
blocking agent (1X PBS (1.37M NaCl, 27mM KCl, 100mM Na2HPO4, 18mM KH2PO4), 
0.1% TritonX-100, 1% BSA, 1% donkey serum) overnight.  Sections were then incubated 
free floating with primary antibodies for seven days, rocking at 4°C.  The long duration of 
incubation was used to promote better antibody penetration. Primary antibody dilution 
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solutions were removed and sections washed four times with PBT on a shaker at room 
temperature (8 minutes/wash).  Sections were next incubated with secondary antibodies for 
two days. Secondary antibody dilutions were removed and sections washed as described 
above.  Sections were then mounted on glass slides using ProLong Gold mounting media 
with DAPI (Life Technologies P36935).  Slides were sealed and stored at 4°C.  Each slide 
contained one section from each of the four treatments (eribulin and its vehicle, paclitaxel 
and its vehicle, Figure S1A), all stained simultaneously with the same antibody solution. 
 
Fluorescence microscopy 
Images were collected using an Olympus Fluoview 1000 Spectral confocal system 
equipped with 405nm, 488nm, 559nm, and 635nm laser lines, and PMT detectors.  Each 
slide containing one section from each of the four treatments and incubated in the same 
antibody solution was imaged with the same exposure settings, determined by identifying the 
brightest-fluorescing section on each slide. 20 m sample depths of two sections from each 
nerve (one relatively proximal and one relatively distal) were imaged by sequential laser 
scanning and 0.5μm step size with an Olympus PLANAPOSC 60x (1.40 NA) high refractive 
index oil immersion objective. In practice, we imaged and assessed 120 m of tissue from 
each end of the 0.75 cm nerve length. This corresponds to 20 m sections for each α-tubulin, 
acetylated tubulin, EB1 and EB3, or 80 m total from each end.  Two additional sections 
were cut from each end for backup and/or testing of other antibodies. As noted above, all 
sections were also stained with anti-MBP and anti-phosphoneurofilament. Where applicable, 
the anti-MBP and anti-phosphoneurofilament signals in these additional sections were 
included in the statistical analyses. 
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Image and Statistical Analysis 
Images from each slide were imported into Imaris Version 7.5.2 (Bitplane, Zurich, 
Switzerland) and rendered into three dimensional maximum intensity z-stack projections for 
analysis.  To assess changes in gross morphological structure, nuclei, myelin and axons were 
identified using DAPI stain, anti-myelin basic protein and anti-phosphoneurofilament, 
respectively.  Using the Imaris software surfaces tool, we identified nuclei, myelin sheaths 
and axons based on the fluorescent signal from their appropriate antibody or stain, manually 
thresholding signal to background noise.  To maintain consistency in object identification in 
similarly treated samples, one set of threshold parameters was applied to those sections 
stained with the same antibody solutions and imaged with the same microscope settings. 
After identification, these objects were counted automatically. Signs of axon degeneration, 
defined as solid, circular regions of myelin lacking a phosphoneurofilament signal, were 
identified and counted manually and compared with the total number of myelin objects 
identified by the software.  For axon density measurements, the image stack was flattened in 
Fiji using the maximum intensity setting and the number of axons per region of interest 
(defined by phosphoneurofilament signal) was quantified using Imaris. 
In order to quantify fluorescence changes, fluorescence values were collected and 
normalized within each slide first, before comparisons were made between slides. 
Normalization of axonal Cy2 fluorescent signals (depicted in Supplementary Figure S1) was 
accomplished by first identifying the axonal region using the anti-phosphoneurofilament 
(PNF) signal to mask the axon regions specifically differentiating axons from surrounding 
Schwann cells or other cell types present.  The raw values of Cy2 fluorescence were 
determined for each axonal region within the treatment field of view.  The mean Cy2 signal 
per axon was calculated for each treatment to give the “treatment mean.” These values were 
` 
 35 
normalized by dividing each treatment mean by the sum of all four treatment means per 
slide.  This method was employed in order to retain the natural variability seen in vehicle 
treatments. 
Student’s T-tests with Bonferroni correction for multiple comparisons were used to 
identify significant differences in mean comparisons of the drug groups to their respective 
vehicles and between the two drug treatment groups, (*p<0.0167, **p<0.003, ***p<0.003). 
In some cases, the singular comparison of the drug to appropriate vehicle group by Student’s 
T-test provided additional insight. 
 
Results 
Paclitaxel and eribulin differentially induce morphological changes 
 We began our analyses by quantifying the neurodegenerative effects of paclitaxel and 
eribulin on sciatic nerve axon density, defined by anti-phosphoneurofilament (PNF) signal, 
in cross-sections of nerves from drug treated mice and vehicle treated controls. Paclitaxel 
treatment resulted in a statistically significant 30% reduction in axon density (196.3 ± 18.52 
axons per 10
4 μm2 compared to 281.8 ± 22.2 axons per 104 μm2 for its vehicle control; 
Figures 1A, 1B, 2A and 2B). In contrast, eribulin administration generated a 21% reduction 
in axon density (234.1 ± 18.52 axons per 10
4 μm2 compared to 296.6 ± 18.43 per 104 μm2 for 
its vehicle controls (mean ± SEM,; Figure 1A, 1B, 2C and 2D).  While neither of these 
reductions are statistically significant when compared using a Bonferroni corrected Student’s 
T-test, it appears that the densities reported here trend toward axonal loss after treatment 
with both eribulin and paclitaxel. 
 We next sought to examine the effects of paclitaxel and eribulin upon axon-myelin 
morphology by quantifying the extent of fiber disruption in cross-sections of sciatic nerves 
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harvested from drug-treated mice relative to vehicle treated, control animals. Paclitaxel 
treatment increased the percent of observed signs of axon degeneration relative to total 
myelin positive objects.  “Signs of axon degeneration” are defined as structures with clear 
anti-myelin basic protein (MBP) signals but lacking any anti-PNF signal (Figure 1B-D and 
figure 2). Specifically, we observed 6.6% of myelin sheaths (anti-MBP stained objects) in 
paclitaxel treated nerves exhibiting signs of axon degeneration (vs. 0.21% for vehicle treated 
nerves; p<0.0003). In contrast, eribulin induced three fold fewer degenerative axons (2.2% 
vs. 0.32% for vehicle treated nerves; p<0.0003). Additionally the difference between 
paclitaxel and eribulin treated groups is also statistically significant (p<0.003).  Similar 
degenerative events have been described in several instances of neuronal toxicity and injury, 
where the space normally occupied by the axon is lost and has been replaced by myelin 
(Muguruma et al. 2006; Schnaar et al. 2014; Wozniak et al. 2011). Additionally, in nerves 
from both paclitaxel and eribulin treated mice, we qualitatively observed an increase in 
myelin fragmentation (thinning and discontinuity of sheath) that often lacked an associated 
phosphoneurofilament stain (For example, see 2E-H). Given that these morphological 
changes were almost exclusively observed in tissue from drug treated mice, we conclude that 
these are treatment induced changes. 
Finally, we occasionally observed an unusual morphology, specifically, a thinly 
myelinated axon fiber within a separated and larger diameter concentric myelin ring, which 
we have termed a “halo” or “double ring”.  (Figure 2D, 2H [see arrows]).  This feature was 
more commonly observed in eribulin than paclitaxel treated nerves, and very infrequent in 
vehicle treatments. 
We next hypothesized that there could be changes among the non-neuronal cell 
population within the nerve in response to neurodegenerative processes.  As the cell nuclei 
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for sciatic nerve axons are located within the dorsal root ganglia far from the site of our 
sectioning, any nuclei present in our images must be non-neuronal.  We quantified the 
population of nuclei present in the sections by staining with DAPI (Figure 3A, 3B).  
Paclitaxel treatment significantly increased the average number of non-neuronal nuclei 
present from 28.0 ± SEM 1.4 per 10
4
 μm2  in the vehicle control to 43.8 ± SEM 2.0 per 104 
μm2 in the paclitaxel treated nerves (p<0.0003). In contrast, there was no significant 
difference in the average number of nuclei present in eribulin treated nerves (29.48 ± SEM 
1.4 per 10
4
 μm2 ) versus vehicle treated nerves (27.2± 1.3;  per 104 μm2 ).  
In summary, paclitaxel more potently induced deleterious morphological effects, 
correlating with its greater probability of inducing severe CIPN relative to eribulin.  
 
Paclitaxel and eribulin differentially affect tubulin composition  
Axons of long peripheral neurons are highly sensitive to changes to the normal 
balances between microtubule stability, dynamic instability and changes in tubulin post-
translational modifications (Almeida-Souza et al. 2011; Avila et al. 1994; Matsuyama and 
Jarvik 1989). Given that paclitaxel and eribulin each possess different mechanistic 
capabilities targeted at microtubules, we hypothesized that sciatic nerves from drug treated 
mice might exhibit drug specific effects upon their microtubule biochemistry. We stained 
nerves from drug-treated and vehicle-treated mice with antibodies specific to -tubulin and 
acetylated tubulin. Axons from eribulin-treated sciatic nerves exhibited a marked, 
statistically significant 2.6 fold increase in -tubulin signal, from 12.6± SEM 3.0 
fluorescence units for controls to 32.5± SEM 3.7 fluorescence units for eribulin treatment 
(p<0.0167; Figure 4A, 4B). Axons from paclitaxel treated mice trended toward a smaller 
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increase in -tubulin signal relative to vehicle treated mice (1.9 fold; 16.4 ± SEM 2.7 and 
8.5 ± SEM 1.1, respectively (p=0.0246 (p>0.167), and p<0.0167 when paclitaxel and 
eribulin groups are compared, Figure 4A, 4B). While not statistically significant when the 
multiple comparison penalty is applied with a minimum significance threshold 0.0167, the p 
value is significant when a standard Student’s T-test is applied to singularly test the 
difference between the means of paclitaxel and its vehicle.  Increased tubulin levels have 
been observed as a result of paclitaxel treatment in multiple cell types (Banerjee 2002; 
Ranganathan et al. 1998), we therefore believe that this increase is worth consideration. 
These inductions are especially remarkable considering the high abundance of tubulin in 
neurons under normal conditions, especially in axons. To control for the artifactual 
possibility that these increased signals resulted from a constant signal being concentrated 
into a smaller area because of axon diameter constriction, we quantified the axon surface 
area and average axon diameters for paclitaxel-treated, eribulin-treated and vehicle-treated 
nerves. No changes in either parameter or G-ratio (outer diameter of the myelin sheath to the 
diameter of the axonal PNF signal, supplemental figure S2) were observed. Additionally, α-
tubulin fluorescence intensity did not correlate positively with axon size (Figure S3) 
We next assessed changes in tubulin acetylation, a post-translational marker of stable 
microtubules. Not surprisingly given its mechanism of action, paclitaxel notably increased 
axonal acetylated tubulin expression relative to vehicle controls by 4.6 fold (16.8 ± SEM 5.1 
and 3.6 ±SEM 1.0, respectively; p=0.0349; Figure 4C, 4D). This data demonstrates a clear 
trend supported by the well-established notion that paclitaxel increases microtubule 
acetylation in treated cells (de Pennart et al. 1988; Piperno et al. 1987). However, given that 
eribulin can promote microtubule depolymerization in vitro and upon short term 
administration to cultured cells, it was surprising to observe that eribulin treatment 
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dramatically increased axonal acetylated tubulin expression relative to vehicle controls by 
11.7 fold (51.8 ± SEM 3.01 and 4.4 ± SEM 0.24, respectively; p<0.0003; Figure 4C, 4D), 
demonstrating a remarkably greater increase in tubulin acetylation compared to paclitaxel 
(p<0.0003). Similarly to α-tubulin, this effect was not dependent upon axon size 
(Supplemental Figure S3).   
These quantitative analyses allow us to calculate the effect of these two drugs upon 
the ratio of acetylated tubulin to total tubulin relative to their vehicle controls; this ratio 
should be a measure of drug induced microtubule stability (Table 1). Eribulin treatment 
increases the acetylated tubulin to total tubulin ratio by 4.5 fold relative to its vehicle control 
whereas paclitaxel treatment increases this ratio by only 2.4 fold relative to its vehicle 
control.  
 
Eribulin but not paclitaxel treatment increases the abundance of EB1; neither drug 
affects EB3 levels 
The microtubule End Binding proteins 1 and 3 (EB1 and EB3) are two highly 
conserved microtubule binding proteins that selectively track with the plus ends of growing 
microtubules (Akhmanova and Steinmetz 2008; Jiang and Akhmanova 2011; Jimenez-
Mateos et al. 2005; Moughamian et al. 2013).  As a result, increased quantities of EB1and/or 
EB3 are indicative of an increase in the number of growing microtubule ends. Treatment 
with eribulin induced a ~2.2 fold increase of immunofluorescence signal for EB1 (p<0.0003) 
relative to vehicle controls (26.8 ± SEM 0.9 versus 12.0 ± SEM 0.7, respectively; Figure 5A, 
5B) and was significantly different compared to the tissue from paclitaxel treated mice 
(p<0.0003).  This effect is apparent in axons with a wide range of diameters, as 
demonstrated in heat maps of tissue sections showing the relative intensity of EB1-
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associated fluorescence (Figure S3).  In contrast, paclitaxel did not cause a significant 
change in the quantity of axonal EB1compared to controls (12.2 ± SEM 1.4 and 10.7 ± SEM 
0.57, respectively; Figure 5A). On the other hand, EB3 levels were slightly reduced with 
paclitaxel treatment compared to controls (12.4 ± SEM 0.9 and 15.6 ± SEM 0.5, 
respectively; p<0.05). In contrast, eribulin treatment did not statistically affect EB3 levels 
relative to controls (Figures 5C, 5D).  
Using the same rationale as used above for acetylated and total tubulin, we calculated 
the ratio of EB1 and EB3 to total tubulin for each drug treatment relative to its control. 
These ratios should be indicators of drug-induced microtubule growing events (Table 1). 
The EB1 to tubulin ratio is higher following eribulin treatment than following paclitaxel 
treatment, suggesting greater microtubule growth in long-term eribulin treated nerves 
compared with long-term paclitaxel-treated nerves.  The EB3 to tubulin ratio is the same 
following eribulin and paclitaxel treatment. 
 
Discussion 
In order to begin to identify and dissect molecular mechanisms underlying the 
initiation and progression of anti-cancer chemotherapy-induced peripheral neuropathy, we 
compared drug-induced changes in sciatic nerve tissue between mice treated with one of two 
microtubule targeting chemotherapeutic agents - paclitaxel, a drug commonly used in the 
clinic that causes relatively high frequencies of severe peripheral neuropathy and eribulin, a 
less commonly used drug that induces a lower frequency of severe neuropathic side effects.  
We sought to ask how these two different microtubule targeting drugs affect mouse sciatic 
nerve morphology and biochemistry. From our observations of both motor and sensory 
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neurons (both of which may be affected in severe neuropathy), we seek to pose testable 
hypotheses focusing upon the induction and progression of peripheral neuropathy.   
Our most important results are: 
1. Both paclitaxel and eribulin trended toward axon loss; 
2. Systemic administration of paclitaxel, and to a lesser extent eribulin increased signs 
of axon degeneration 
3. Systemic administration of paclitaxel, but not eribulin,  
a. increased the abundance of non-neuronal cells; 
b. slightly decreased the level of axonal EB3   
4. Systemic administration of eribulin, and to a lesser extent paclitaxel 
a. induced total tubulin accumulation; 
b. induced tubulin acetylation, a marker for microtubule stability 
5. Systemic administration of eribulin, but not paclitaxel 
a. increased the abundance of myelin halos/double rings 
b. increased the abundance of EB1, a marker for growing microtubules 
 
These observations demonstrate that paclitaxel and eribulin each exert quantitatively 
and qualitatively distinct effects on axon degeneration, myelin morphology and microtubule 
composition in mouse sciatic nerve tissue. Further, the data indicate that paclitaxel treatment 
is much more potent than eribulin with respect to inducing signs of axon degeneration, while 
eribulin more effectively induces potentially positive biochemical effects (i.e., increased 
levels of tubulin, tubulin acetylation and EB1). Changes in axon density trended clearly 
toward axon loss within both drug treated groups, but were not statistically significant at our 
statistical thresholds.  Three reasons that may account for the lack of statistical significance 
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in observed axon losses despite these trends are (i) that our sampling region within the mid-
thigh region of the mouse sciatic nerve is a relatively great distance from the distal 
extremities where symptoms are most pronounced and nerve endings where high degrees of 
fiber loss has been observed in previous studies (Boyette-Davis et al. 2011), (ii) there may be 
a high degree of individual variability in the number of neurons that retract over that distance 
and (iii) mouse to mouse axon density may vary over a short distance of sciatic nerve and 
experimental logistics prevented tight control over the exact position of nerve.  Given this, 
we believe that a stronger measure of axon degeneration is found within our assessment of 
positive signs of axon degeneration relative to axons present. This data demonstrates clear 
changes upon drug treatment and between paclitaxel and eribulin groups. Eribulin does 
induce more myelin halos compared to paclitaxel (and absent in vehicle controls), which 
may represent a relatively early stage of the neurodegenerative process. These observations 
are consistent with recent work by Vahdat et al., and colleagues who found that the onset of 
eribulin-induced neuropathy occurred later than that induced by the microtubule stabilizing 
drug ixabepilone, which normally displays a higher incidence of neuropathy than paclitaxel 
(Steinberg 2008; Vahdat et al. 2013). 
Based on these observations, we propose that the greater clinical probability of 
severe peripheral neuropathy by paclitaxel relative to eribulin may be a function of its 
greater relative damage to the nervous system coupled with eribulin’s ability to promote a 
more stable and growth oriented microtubule network than does paclitaxel. With respect to 
the latter, we note that the regulation of microtubule dynamics is a balancing act between 
microtubule shortening events, microtubule lengthening events and a population of stable 
non-changing microtubules. We propose that the long-term combined effects of increased 
total tubulin (providing more building blocks for microtubule assembly), tubulin acetylation 
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(indicating greater microtubule stability) and EB1 (suggesting more growing microtubule 
ends) more than compensate for eribulin’s inherent ability to suppress microtubule growth 
events (see below for more discussion). The net effect is an extensive and functional 
microtubule network. Such a compensatory or neuroprotective mechanism could also be at 
play in electrophysiological experiments demonstrating that paclitaxel but not eribulin 
causes a loss of caudal nerve amplitude and reduced conduction velocity (Wozniak et al. 
2011); indeed, eribulin administration actually increases caudal nerve amplitude and exhibits 
no reduction in conduction velocity in these studies.  Wozniak et al. (2011) also observed 
signs of axon degeneration, similar to those described in this work, more frequently in tissue 
from paclitaxel treated mice as compared to eribulin treated mice, correlating with the 
functional deficits seen in paclitaxel, but not eribulin.  Unfortunately, due to the higher level 
of drug required to achieve a maximum tolerated dose, we are unable perform functional 
assessments on the same mice receiving drugs.  However, based upon previous data, we 
predict that paclitaxel would demonstrate greater functional deficits compared to eribulin, 
but lack the ability to make direct conclusions at this time. 
 
Mechanistic considerations 
Perhaps the most surprising observations presented here are that long-term eribulin 
treatment leads to a marked increase in the abundance of both total tubulin and acetylated 
tubulin. The simplest interpretation of these observations is that eribulin treatment results in 
an increase in the abundance of stable microtubules. This is surprising because eribulin is 
generally viewed as a microtubule depolymerizing agent. However, it is important to 
emphasize that the previously demonstrated microtubule depolymerizing activity of eribulin 
has been observed in short-term in vitro biochemical reactions or when added to 
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proliferating cultured cells for a few hours. In contrast, our investigations were performed 
following two weeks of systemic drug administration to mice and focused primarily on post-
mitotic neurons. Mechanistically, one could imagine that microtubules in the sciatic nerve 
might exhibit net depolymerization upon initial exposure to eribulin. However, either 
depolymerization itself or some other aspect of eribulin action leads to subsequent regulatory 
mechanisms that induce tubulin levels, tubulin acetylation levels, EB1 levels and perhaps 
additional proteins. As one possibility, the binding of eribulin to free tubulin subunits may 
inactivate the normal tubulin auto-regulatory mechanism by which free tubulin subunits bind 
to tubulin mRNA and thereby promote tubulin mRNA degradation, which in turn leads to a 
reduction of tubulin protein  synthesis (Gay et al. 1987; Pachter et al. 1987). By this 
mechanism, eribulin would inhibit tubulin mRNA turnover, leading to the accumulation of 
increased levels of tubulin mRNA and tubulin protein. Together, these stabilizing effects 
could compensate for the destabilizing effects of eribulin on the microtubule network, 
leading to a more robust and stable microtubule network that can function relatively 
effectively. These effects may be neuronal specific, thereby providing protection from the 
drug for neurons while not compromising the action of the drug on tumor cells. 
Another possibility that must be considered is that perhaps eribulin does not 
effectively get into the nerve and this underlies its reduced frequency of severe CIPN. We 
think this is extremely unlikely.  Indeed, recent work from some of our labs directly assessed 
the pharmacokinetics and peripheral nerve distribution of eribulin and paclitaxel following 
administration via the caudal vein. Both drugs rapidly penetrated the sciatic nerves and 
dorsal root ganglia, with maximal concentrations achieved within 15 minutes. With the 
passage of time, dose normalized area under the curve in the sciatic nerves was actually 
greater for eribulin than for paclitaxel (unpublished data, KW, BAL, BSS). These findings 
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indicate that limited peripheral nerve exposure is likely not the underlying mechanism for 
the differential propensity of eribulin and paclitaxel to produce neurotoxicity. 
The increase in total tubulin in both eribulin and paclitaxel treated cells provides an 
enormous supply of additional microtubule building blocks. Given sufficient GTP and 
growth and/or stabilization regulatory cues, this would enable the neuronal cells to markedly 
augment their microtubule networks. The increased ratios of acetylated tubulin to total 
tubulin in drug versus vehicle axons suggest drug induced microtubule stability. The fact 
that this ratio is 1.9 fold greater in eribulin treated nerves than in paclitaxel treated nerves 
(4.5/2.4; Table 2) implies that the microtubule network in eribulin treated nerves is 
considerably more stable than in paclitaxel treated nerves. It is also interesting to consider 
recent work demonstrating that tubulin acetylation can also influence the interaction between 
MAPs and microtubules. For example, recent work suggests that tubulin acetylation may, in 
part, control the affinity between microtubules and kinesin (Almeida-Souza et al. 2011; 
Dompierre et al. 2007; Reed et al. 2006; Walter et al. 2012). 
Increased levels of EB1 may also play an important role in eribulin’s relatively 
benign induction of CIPN via a number of possible mechanisms. Similarly to acetylation, the 
EB1 to total tubulin ratio in drug treated versus control axons is higher for eribulin than for 
paclitaxel treatment. This higher ratio of EB1 to total tubulin suggests a greater proportion of 
growing microtubule plus ends in eribulin versus paclitaxel treatment. Additionally, 
evidence suggests that EB1 can promote de-novo microtubule nucleation (Vitre et al. 2008). 
Finally, EB1 is known to influence microtubule dynamics both directly and indirectly.  Upon 
binding directly to microtubule plus ends EB1 recognizes GTP tubulin and an intermediate 
form as tubulin changes from GTP to GDP bound, preferentially binding the intermediate 
form and increasing the rate of tubulin maturation to stable, polymerized GDP-bound tubulin 
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(Kumar and Wittmann 2012; Maurer et al. 2012). This action directly influences microtubule 
dynamicity. EB1 can also influence microtubule dynamics indirectly via its recruitment of 
other proteins known to influence microtubule dynamics, including +TIPS such as the CLIP 
family members, CLASPs and APC as well as XMAP (Akhmanova and Steinmetz 2008).  
 
Increased population of non-neuronal cells in paclitaxel-treated nerves 
Our data demonstrate that paclitaxel but not eribulin treatment increases the number 
of non-neuronal nuclei (and hence cells) present in sciatic nerve tissue. Schwann cells likely 
account for the majority of nuclei found in tissue from vehicle and eribulin treated mice. 
However, the identity of the additional cells seen in paclitaxel treated nerves is less obvious.  
Increased Schwann cell division could account for the increased nuclear population, but 
invasion by immune cells responding to degenerative axons may also contribute to the 
effect. Invasion of the sciatic nerve by immune cells and release of pro-inflammatory factors 
have been observed after nerve injury and neuropathic pain-inducing paclitaxel treatment 
(Janes et al. 2014; Peters et al. 2007a; Peters et al. 2007b; Rotshenker 2011). 
 
Eribulin and Paclitaxel: Anti-Cancer Efficacy 
The demonstration that eribulin induces less frequent severe CIPN than the widely 
used paclitaxel raises the question of its relative anti-cancer efficacy relative to paclitaxel. A 
lower incidence of severe peripheral neuropathy would be most meaningful if it were 
coupled with equal or greater anti-cancer efficacy. Unfortunately, to date there have been no 
completed clinical studies directly comparing the anticancer efficacies of eribulin and 
paclitaxel in the clinical setting.  That said, eribulin was FDA approved in 2010 as a third 
line therapy for patients with metastatic breast cancer who had previously received at least 
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two prior chemotherapy regimens, including an anthracycline and a taxane.  At the time of 
the pivotal Phase III EMBRACE trial which led to the FDA approval, there was no standard 
of care for third line metastatic breast cancer, so EMBRACE was designed, in conjunction 
with the FDA, as a two-arm study of eribulin monotherapy versus “treatment of physician’s 
choice” (TPC), essentially capturing the individual judgements of hundreds of oncologists’ 
decisions as to the best personalized treatment of those specific patients (Cortes et al., Lancet 
2011).  EMBRACE stipulated that enrolled patients must have progressed within 6 months 
or less of the latest chemotherapy (Cortes et al., Lancet 2011).  As such, the statistically-
significant 24% increase in median overall survival between the two groups (13.1 months 
versus 10.6 months for eribulin versus TPC, respectively) indicates that many patients 
enjoyed prolonged survival on the eribulin arm despite the fact that they had previously 
progressed on taxane-containing therapies.  In addition, the preclinical work of Towle et al., 
(2001), demonstrated that eribulin is more effective at considerably lower doses than 
paclitaxel (at empirically determined MTD levels) in four different human tumor xenograft 
growth models in mice: potency differentials for eribulin versus paclitaxel based on 
complete tumor suppression ranged from 20- to 100-fold for different human tumors. 
Additionally, in these in vivo studies, eribulin consistently showed a wider therapeutic 
window compared to paclitaxel.  Finally, eribulin showed an average 4.1-fold increased 
potency compared to paclitaxel on a molar basis in a library of 8 human cancer cell lines, 
with ratios in the individual lines ranging from 2.0-fold to 27.8-fold.  We conclude that, 
although direct head-to-head comparisons of eribulin versus paclitaxel have yet to be 
reported in the clinical setting, existing clinical evidence from the EMBRACE Phase III 
clinical trial pointing to eribulin activity after progression on taxanes, coupled with 
consistent preclinical evidence of greater potency both in cancer cell lines and human tumor 
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xenograft models, make a compelling case that eribulin is either an equipotent or more 
potent anticancer agent relative to paclitaxel.  In this context, the apparently lower 
neuropathic effects of eribulin relative to paclitaxel in both the clinic and laboratory settings 
can be viewed as not simply a consequence of lower overall potency, but rather a bona fide 
reduction in one of the most significant and troubling side effects of treatment with these 
two agents.   
   
Summary 
Work presented here leads us to hypothesize that long-term treatment with eribulin 
generates a more functional microtubule cytoskeleton than does similar treatment with 
paclitaxel, accounting at least in part for the reduced levels of severe CIPN observed with 
eribulin-treated versus paclitaxel-treated patients. With this foundation, future investigations 
will include testing this hypothesis mechanistically, both in animal and cell culture models. 
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Figures 
 
Figure 1. Paclitaxel and Eribulin Differentially Affect Sciatic Nerve Morphology  
A. Quantification of axon density per 10
4
 μm2.  (n = 5p>0.0167) B. Representative confocal images of 
paclitaxel and eribulin treated sciatic nerves; phosphoneurofilament (yellow), myelin basic protein (red). White 
arrow heads indicate observed signs of axon degeneration. C. Quantification of observable signs of axon 
degeneration per total number of anti-myelin basic protein (MBP) stained objects, **p<0.003, ***p<0.0003). 
D. Enlarged region of paclitaxel image to show axon degenerative events from boxed area indicated on panel 
C. Scale bar 20μm. 
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Figure 2. Paclitaxel and Eribulin differentially disrupt normal myelin morphology and differentially 
lead to degradation of myelin sheaths. A, B. Phosphoneurofilament (PNF; yellow) and myelin basic protein 
(MBP; red) expression in sciatic nerve tissue from mice treated with the vehicle for paclitaxel and paclitaxel.  
Tissue from mice treated with paclitaxel shows frequent signs of axon degeneration (white arrowheads) and 
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increased fragmentation.  C, D. PNF and MBP expression in vehicle for eribulin and eribulin treated nerves.  
Tissue from mice treated with eribulin reveals fewer signs of axon degeneration but occasional instances of 
thinly myelinated axon fibers and separation of myelin layers (“halos”; white arrows) accompanied by myelin 
fragmentation.  E, F. Enlarged views of vehicle paclitaxel and paclitaxel treatments, respectively.  G, H. 
Enlarged regions of vehicle eribulin and eribulin respectively.  Scale bars 10μm. 
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Figure 3. Paclitaxel but not Eribulin treatment leads to increased numbers of non-neuronal nuclei. A.  
Quantification of non-neuronal nuclei present in drug and control nerves (n=5, ***p< 0.0003) B. 
Representative images showing DAPI stained nuclei (white) and myelin basic protein (red) for reference; scale 
bar 20μm. 
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Figure 4. Eribulin induces greater -tubulin abundance and tubulin acetylation than Paclitaxel. A. 
Quantification of tubulin levels in drug and vehicle treated nerves.  Eribulin increased axonal levels of tubulin 
~2.6 fold relative to control (n=5, *p<0.0167) while paclitaxel increased axonal tubulin ~1.9 fold 
(n=5,p=0.0246 (p>0.0167))(Paclitaxel compared to eribulin, *p<0.0167). B.  Representative images 
immunostained for α-tubulin (green) and quantified within the axon region defined by PNF signal (yellow). 
Acquisition settings were adjusted to the brightest fluorescing tissue section. Therefore,  because of the 
pronounced difference in relative fluorescence, the less intensely fluorescing sections appear quite dim.  Please 
see materials and methods for more detail C. Quantification of acetylated tubulin levels in drug and control 
nerves.  Paclitaxel treatment increased axonal acetylated tubulin ~4.6 fold relative to control (n=5, p= 0.0349 
(p>0.0167)) while eribulin increased axonal acetylated tubulin ~11.7 fold compared to its control (n=5, 
***p<0.0003, paclitaxel compared to eribulin: **p<0.003). D. Representative images of sciatic nerve tissue, 
acetylated tubulin (green) was quantitated within the axon region defined by PNF. Scale bars 20μm.  
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Figure 5. Eribulin but not Paclitaxel induces EB1 abundance in axons and Schwann cells; Paclitaxel but 
not Eribulin reduces EB3 abundance in axons and Schwann cells. A. Quantification of EB1 levels in drug 
and control nerves. Axonal EB1 in eribulin treated nerves increased ~2.2 fold as compared to controls (n=5, 
***p<0.0003). No change is observed following paclitaxel treatment as compared to its vehicle. B. 
Representative nerve section images; axons are identified by phosphoneurofilament (PNF, yellow), EB1 
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(green). Qualitatively, an increase in EB1 abundance was observed in surrounding Schwann cells. C. EB3 
levels did not significantly change with either paclitaxel or eribulin treatment. D. Representative nerve section 
images; axons are identified by anti-phosphoneurofilament (PNF, yellow, left panel), EB3 (green, middle 
panel), merge seen in right panel. Scale bars 20μm. 
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Table 1. Fold change in abundance following drug treatment (drug/vehicle) 
 
Erb 
 
Pac 
α-tubulin 2.6 
 
1.9 
Ac-α-tubulin 11.7 
 
4.6 
EB1 2.2   1.1 
 
 
Table 2. Ratios of fold change in abundance following drug treatment 
 
Erb 
 
Pac 
Ac-α-tubulin 4.5 
 
2.4 
EB1 0.85   0.58 
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Supplementary Figures 
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Fig. S1. Quantification and Normalization of Cy2 fluorescent signal.  Sections were 
incubated in appropriate primary and secondary antibody solutions.  Control and drug treated 
sections that had been incubated with the same antibody solution were mounted on a slide as 
in (a) for imaging.  Images were imported into the Imaris software package to visualize 3D 
reconstructed stacks and complete further analysis.  b. In order to quantify the axonal 
specific cy2 (eg. α-tubulin in this case, green) fluorescence in the 3D reconstructed image 
stacks (B.1) we used merged images of α-tubulin (green) and phosphoneurofilament (PNF, 
an axon marker, yellow) as in B.2 and B.4 (single axon view).  Axon regions were defined 
by PNF signal, manually threshholded to separate signal from noise.  The Imaris surface tool 
determines the volume occupied by the thresholded PNF signal and outlines a boundary that 
defines the axon volume (B3 and B5 (single axon view), purple).  With boundaries 
established for axonal regions, we the amount of cy2 (e.g. α-tubulin) fluorescence within the 
axon boundary is queried. The Cy2 fluorescence value identified per axon is represented by 
the green boxes (c).  All axons per treatment were averaged to give the treatment mean. The 
treatment means were then normalized by dividing each treatment mean by the sum of 
treatment means observed on the slide. Each normalized value was multiplied by 100, to 
allow comparison of relative fluorescence units between sections processed separately.  This 
was repeated twice per nerve for each of 5 nerves per treatment to obtain a nerve value.  The 
mean of the 5 nerve values is represented in the graphs in main figures 
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Fig. S2 Axon properties as determined by Imaris software. a. axon surface area 
identified by 2D rendering of z-stack using Imaris software, b. mean axonal diameter and c. 
g-ratio.  None of these three parameters are significantly different in axons from drug-treated 
mice as compared to their vehicle treated controls.  d. diagram defining G-ratio as the axon 
diameter (x) divided by the myelin outer diameter (y) 
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Fig. S3 Heatmaps illustrating α-tubulin, acetylated tubulin, or EB1 signal intensity 
within the axon region defined by anti-phosphoneurofilament (PNF) signal.  Each 
object represents a single axon and the color represents the intensity of the indicated 
antibody signal within that axon.  Cool colors represent relatively low intensities and warm 
colors represent relatively high intensities.  The relative size of the axon does not appear to 
correlate with the relative intensity of tubulin signals or EB1 signal, thus we infer intensity is 
not size-dependent. Scale bars 20μm. 
 
 
Table S1. Antibodies used for immunofluorescence labeling. 
 
Primary Antibodies Company Catalog 
number 
Dilution 
used 
Chicken Anti-Myelin Basic Protein Millipore AB9348 1:100 
Mouse Anti- Phosphoneurofilament 
(SMI 31) 
Covance SMI-31R 1:2000 
Rabbit Anti-EB1 Millipore AB6057 1:500 
Rat Anti-EB3 Santa Cruz SC-101475 1:200 
Rabbit Anti-Α Tubulin Millipore 04-1117 1:500 
Rabbit Anti-Acetylated-α-Tubulin Cell Signaling 5335 1:800 
Rat Anti-Tyrosinated Tubulin Abcam AB6160 1:1000 
Rabbit Anti-detyrosinated Tubulin Millipore AB3201 1:500 
Secondary Antibodies    
Goat Anti-Rabbit IgG DyLight 488 Jackson 
ImmunoResearch 
111-485-003 1:200 
Goat Anti-Rat  IgG DyLight 488 Jackson 
ImmunoResearch 
112-485-003 1:200 
Goat Anti-Mouse IgG DyLight 649 Jackson 
ImmunoResearch 
115-495-003 1:200 
Goat Anti-Chicken IgY DyLight 488 Jackson 
ImmunoResearch 
103-165-155 1:200 
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Chapter III. Rapid recovery from several morphological and biochemical effects of 
chemotherapy-induced neuropathy following paclitaxel and eribulin in mouse sciatic 
nerves 
 
Summary 
Improvements in cancer treatment with microtubule-targeting agents (MTAs) have led to 
a growing population of cancer survivors.  As the focus shifts to quality of life during and 
after chemotherapy, the reversibility of chemotherapy-induced peripheral neuropathy 
(CIPN), a disabling and potentially permanent side effect of MTAs is becoming increasingly 
important.  The time to onset, frequency, and recovery from CIPN varies between the 
common MTAs paclitaxel and eribulin and is manifested through unknown mechanisms.  
Previously, we found that after 2 weeks of maximum tolerated doses (MTD) in mice, 
paclitaxel treatment resulted in a 30% reduction in sciatic nerve axons per unit area while 
eribulin generated a 21% reduction compared to controls (Benbow et al. 2016).  Paclitaxel 
also increased the frequency of myelin abnormalities more significantly than did eribulin 
(6.6% and 2.2% of total axons, respectively), as well as led to an increase in the number of 
non-neuronal nuclei in sciatic nerves.  Biochemically, paclitaxel and eribulin both induced 
α-tubulin expression (1.9- and 2.5-fold, respectively) and tubulin acetylation (5- and 11.7-
fold, respectively).  Eribulin but not paclitaxel induced EB1 expression 2.2 fold.  Here, we 
extended these comparative studies to acquire a more detailed understanding of the recovery 
from drug treatment.  Mice were dosed with maximum tolerated doses of eribulin (1.2 
mg/kg), paclitaxel (30 mg/kg), or their respective vehicles; each drug was administered 
intravenously 3 times per week for 2 weeks and mice were followed for up to 6 months after 
the completion of dosing.  In paclitaxel-treated mice, axon area density was significantly 
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decreased through 3 months of recovery.  In contrast, axon area density in eribulin-treated 
mice recovered fully from initial deficits by the 2 week time point, with ixabepilone showing 
no change at any time point. Evidence of myelin abnormalities, likely secondary to 
axonopathy, was prominent at 2 weeks and 3 months and was consistently most frequent in 
paclitaxel-treated animals. Also, only paclitaxel-treated mice displayed a significant and 
persistent increase in the number of non-neuronal nuclei at the 2 week, 3 month and 6 month 
recovery time points, although ixabepilone-treated mice showed a similar trend at 2 weeks. 
These additional nuclei were positive for known Schwann cell markers S100B and GFAP, 
indicating that they are likely Schwann cells, the resident glia of the sciatic nerve. 
Biochemically, we found that two weeks into the recovery phase, α-tubulin acetylation in 
eribulin-treated mice returned to control levels while it was greatly reduced but still 
significantly higher than vehicle treated mice in paclitaxel-treated mice. In contrast, axonal 
levels of both α-tubulin and end-binding protein 1 (EB1) rapidly returned to control values at 
14 day from initially induced levels at the end of the MTD treatment in both paclitaxel and 
eribulin treated mice. Overall, mice treated with eribulin and ixabepilone recovered more 
rapidly from drug-induced morphological and biochemical effects than did paclitaxel-treated 
mice. In summary, we found that (i) morphologically, sciatic nerve axons recover more 
rapidly in eribulin and ixabepilone treated animals than in paclitaxel treated animals and (ii) 
biochemically, drug-induced increases in protein expression levels following paclitaxel and 
eribulin treatment are relatively transient.  Taken together, our data in mice indicate a milder 
onset and faster recovery with eribulin and ixabepilone treatment than for paclitaxel. 
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Introduction 
Chemotherapy-induced peripheral neuropathy (CIPN) is a major dose-limiting and 
potentially permanent side effect of cancer treatment with microtubule-targeting agents 
(MTAs).  The anti-tumor activity of MTAs is widely accepted as deriving from their ability 
to alter the normal regulatory mechanisms controlling microtubule dynamics and 
microtubule-based transport that are required for cell survival (Argyriou et al. 2012; Field et 
al. 2014; Jordan and Wilson 2004; Poruchynsky et al. 2015).  While effective in reducing 
tumor growth, the systemic administration of MTAs also exposes non-target tissues, such as 
the peripheral axons that transmit sensory and motor input to their mechanistic actions.  
Such chemotherapeutic assault on peripheral nerves can result in pain, numbness, and 
burning sensations originating in the distal extremities and progressing proximally toward 
the trunk as dosing increases and drug accumulates over time (Dougherty et al. 2004, 
Boyette-Davis et al. 2013).  
CIPN can significantly impact quality of life, both during and after administration of 
MTAs (Cavaletti et al. 2010, Cavaletti et al. 2014, Shimozuma et al. 2009, Dumontet and 
Jordan 2010, Grisold et al. 2012). In fact, CIPN is the most often cited reason for patient-
elected dose reduction during treatment and occasionally necessitates complete cessation of 
chemotherapy (Agryriou et al. 2012, Agryriou et al. 2008, Bhatnagar et al. 2014, Miltenburg 
and Boogerd 2014).  Early discontinuation of chemotherapy is associated with increased 
mortality (Hershman et al. 2011).  Given the key roles played by MTAs in current anti-
cancer therapies, it follows that a more detailed understanding of mechanisms controlling the 
onset and reversibility from CIPN would be extremely valuable, hopefully leading to 
improved strategies to manage CIPN. 
  66 
There is significant variability in the time to onset, duration, and reversibility of 
CIPN among the different classes of commonly prescribed MTAs.  Paclitaxel, of the taxane 
class, is among the most effective antineoplastic agents and is commonly used as a first-line 
treatment for ovarian, breast, and lung cancers (Rowinsky et al. 1993, Choy et al. 1994).  
However, the high incidence of severe neuropathy in about 30% of paclitaxel-treated 
patients is a significant drawback that can limit its use.  Paclitaxel-induced peripheral 
neuropathy has a median time to clinical onset of 1.1 months, although symptoms can arise 
shortly after the first dose (Forsyth et al. 1997). Often, symptoms improve or resolve within 
the first 3-6 months after discontinuation of treatment, and for the subset of people who 
achieve a full recovery, the median time to total resolution is 9-10 months (Grisold et al. 
2012, Pace et al. 2007, Forsyth et al. 1997).  However, 41-80% of patients experience 
delayed recovery of CIPN symptoms two years after the last dose after paclitaxel while some 
patients never fully recover (de la Morea Barrio et al. 2015, Hershman et al. 2011).  Taken 
together, paclitaxel treatment frequently produces rapid onset and long lasting peripheral 
neuropathy. 
Following the development of paclitaxel resistance, patients may receive 
ixabepilone, an epothilone D analog that induces microtubule stabilization similar to 
paclitaxel.  Treatment with ixabepilone is associated with an incidence of severe sensory 
peripheral neuropathy of 6-21% (Roche et al. 2007, Steinberg et al. 2008, Thomas et al. 
2007, Dreicer et al. 2007).  Compared to paclitaxel, the median time to onset is longer for 
ixabepilone at 2.7 months from the start of treatment but complete resolution is more rapid 
at 2.3 months from the last dose (Perez et al. 2007, Vahdat et al. 2013).   
Paclitaxel and ixabepilone both induce a higher incidence of neuropathy in patients 
than eribulin (Argyriou et al. 2012, Puhalla et al. 2008, Cortes et al. 2011, Vahdat et al. 
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2013).  Eribulin, a halichondrin, is a more recently approved third-line therapy for breast 
cancer with a more favorable safety profile: 7.7% of patients report cases of severe 
neuropathy while undergoing chemotherapy (Cortes et al. 2012).  Compared with paclitaxel 
and ixabepilone, the median time to clinical onset of eribulin-induced neuropathy is more 
delayed (8.3 months from the start of treatment) and symptoms resolve more quickly 
(median time to total resolution of 1.8 months )(Vahdat et al. 2013, Kaufman et al .2014).  
Thus compared with paclitaxel and ixabepilone, clinical data indicates that eribulin produces 
a peripheral neuropathy that is later onset, less severe, and more quickly resolving. 
Cells possess intricate mechanisms to regulate their microtubule networks.  First, the 
concentration of soluble α/β-tubulin dimers regulates polymerization of the dimer subunits 
into microtubules.  Once assembled, post-translational modifications can alter microtubule 
stability and modify microtubule dynamics.  For example, long-lived and stable 
microtubules are known to be decorated with acetyl groups on α-tubulin’s lumenal lysine-40.  
Additionally, microtubule-associated proteins bind and regulate microtubule dynamics.  
End-binding protein 1 (EB1) is a plus-end binding protein and marker of microtubule 
stability that is necessary for scaffolding other proteins at the plus tip (Geraldo et al. 2008; 
Gu et al. 2006; Jaworski et al. 2009).  We have proposed previously that cells must maintain 
the dynamics of their microtubule cytoskeleton within a functional range and that conditions 
(such as induced by MTAs) can lead to neuronal cell dysfunction and eventual 
neurodegeneration (Bunker et al. 2004, Feinstein and Wilson 2005). 
While the taxane, epothilone, and halichondrin classes of MTAs each target 
microtubules, they each exert different binding and kinetic effects on microtubules (Derry et 
al. 1995).  Paclitaxel binds along the length of the inner microtubule surface and prevents 
disassembly, thereby promoting microtubule assembly and stability (Horwitz et al. 1994).  
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The antitumor effect of paclitaxel is predominantly believed to occur via its ability to arrest 
cells in metaphase by preventing chromosome-kinetochore attachment (Jordan et al. 1993, 
Waters et al. 1998, Kapoor et al. 2013).  Similar to taxanes, epothilones exert their effect by 
binding to a site close to or at the taxane binding site and stabilizing microtubules (Bollag et 
al. 1995, Giannakakou et al. 2000, Nogales et al. 1995, Ojima et al. 1999). In contrast, 
eribulin binds to both soluble tubulin subunits as well as microtubules and results in net 
depolymerization of microtubules.  Unlike paclitaxel’s dispersed binding along the 
microtuble lumen, the halichondrin eribulin is known to bind only at the growing plus end of 
microtubules where additional subunits are added to the extending polymer (Smith et al. 
2010). 
Recently, we investigated the effects of paclitaxel and eribulin on the morphology 
and biochemistry of peripheral sciatic nerve axons 24 hours after the last dose of a 2 week 
maximum tolerated dose treatment.  We observed key differences in the propensity of each 
agent to induce deleterious morphology as well as differences in altered protein 
biochemistry.  We proposed that the positive biochemical effects of eribulin (more α-tubulin, 
acetylated-α-tubulin, and EB1) in peripheral axons compensated in part for its deleterious 
morphological effects.  In the present study, we have built upon our previous work by 
determining the extent to which these morphological and biochemical changes persist after 6 
months of recovery following the same two-week maximum tolerated dose animal model.  
We compared the recovery rates of eribulin-, paclitaxel-, and ixabepilone-induced deficits in 
axon density, signs of axon degeneration, abundance of Schwann cell nuclei, and abundance 
of α-tubulin, acetylated α-tubulin, and EB1.  We found that (i) morphologically, sciatic nerve 
axons recover more rapidly in eribulin- and ixabepilone-treated animals than in paclitaxel-
treated animals and (ii) surprisingly, drug-induced increases in protein expression following 
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paclitaxel and eribulin treatment were relatively transient.  Interestingly, the morphological 
effects of ixabepilone were mild compared with paclitaxel and eribulin despite its propensity 
to induce neuropathy in patients.  Taken together, our data in mice indicate a milder onset 
and faster recovery with eribulin and ixabepilone treatment than with paclitaxel. 
 
Materials and Methods 
Antibodies 
The following primary antibodies were used in immunohistochemical analyses:  anti-α-
tubulin (Millipore, 04-1117, 1:100 dilution (Zhang et al. 2011)),  anti-acetylated tubulin 
(Cell Signal, 5335, 1:800 dilution, (Creppe et al. 2009)), anti-EB1 (Millipore, AB6057, 
1:500 dilution, (Vitre et al. 2008), anti-myelin basic protein (Millipore, AB9348, 1:100 
dilution, (Heller et al. 2014), anti-phosphoneurofilament (Covance, SMI-31R, 1:2000 
dilution, (Choi et al. 2008), anti-S100B (Abcam, ab11178 1:500 dilution), and anti-GFAP 
(Abcam, ab7260 1:200).  FITC, Cy3 and Cy5 conjugated secondary antibodies were 
purchased from Jackson Research and used at 1:200 dilutions. 
 
Drugs 
Eribulin mesylate (synthesized at Eisai Research Institute and stored at -80°C degrees in the 
dark) was dissolved in 100% anhydrous DMSO (Sigma-Aldrich, St. Louis, MO) to produce 
a 10 mg/mL stock solution, which was separated into aliquots and stored at -80°C until day 
of administration.  Each administration day the stock solution was thawed and diluted with 
saline to a final concentration of 0.125mg/mL in 2.5% DMSO/97.5% saline and 
administered in a 10 mL/kg volume.  Paclitaxel (LC Laboratories, Woburn, MA) was stored 
at -20°C in the dark was dissolved in 100% ethanol at 10% final volume.  An equal volume 
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of cremophor (10% of final volume) was then added and the mixture re-vortexed for about 
10 minutes.  Immediately prior to injection, ice-cold saline was added to final volume (as 
80% of final) and the solution was maintained on ice during dosing.  Dosing solutions of 
3mg/mL were made fresh daily and administered in a 10 mL/kg volume.  Ixabepilone was 
purchased as part of an IXEMPRA kit (Bristol-Myers Squibb) for clinical administration. 
The ixabepilone solution was prepared according to instructions provided in the package 
insert. The kit consists of 2 vials, 1 containing 47 mg ixabepilone powder and the other 
containing 23.5 mL diluent, which were stored in the refrigerator at 4°C. The total volume of 
the diluent was added to the total amount of powder; therefore, after reconstitution, the 
concentration of ixabepilone in the solution was 2 mg/mL. The diluent supplied consists of a 
sterile nonpyrogenic solution of 52.8% (w/v) purified polyoxyethylated castor oil and 39.8% 
(w/v) dehydrated alcohol. The formulated ixabepilone stock solution (2 mg/mL) was 
immediately aliquoted and stored at -80C until use. On each experimental day, the stock 
solution was diluted by adding 50% ethanol/50% cremophor with subsequent vortexing to 
yield a solution that was 5 times the required dosing concentration. Finally, 4X volumes of 
PBS were added, while vortexing, to achieve a final dosing concentration of 10 mL/kg. 
 
Animal Studies 
Female BALB/c mice (approximately 7–8 weeks old at onset of dosing) were obtained from 
Harlan Laboratories Inc. (Indianapolis, IN) and maintained with free access to water and a 
standardized synthetic diet (Harlan Teklab). Animal housing and procedure room 
temperature and humidity were maintained at 20 ± 2
o
C and 55 ± 10°C, respectively. 
Artificial lighting provided a 12 h light/12 h dark cycle (light 7 a.m.–7 p.m.).  All 
experimental protocols were approved by the Institutional Animal Care and Use Committee 
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of Sobran Inc (Baltimore, MD) and adhered to all of the applicable institutional and 
governmental guidelines for the humane treatment of laboratory animals. 
Mice were randomly assigned into vehicle, eribulin, ixabepilone, or paclitaxel treatment 
group (n= 3). Drugs were administered 3 times per week (Monday, Wednesday, Friday) for 2 
weeks into the caudal vein at a dose that was perviously determined to be the MTD 
(Wozniak et al. 2011), specifically 30 mg/kg, 1.25 mg/kg, and 2 mg/kg for paclitaxel, 
eribulin, and ixabepilone respectively.  Following two weeks, three months or six months of 
recovery after the last dose, mice were deeply anesthetized with 10% chloral hydrate and 
euthanized by transcardial perfusion with PBS followed by 4% paraformaldehyde in 0.1 mM 
phosphate buffer, pH 7.4, for 10–15 min.   Subsequently whole mid-thigh sections of sciatic 
nerve were dissected and placed in perfusion fixative at 4
o
C. 
 
Tissue Preparation 
Fixed whole sciatic nerves were processed as described previously (Benbow et al. 2016).  
Briefly, sciatic nerves were embedded in 10% agarose (w/v) dissolved in 1X PBS containing 
0.01% sodium azide and cross-sectioned in 100μm steps from distal to proximal end using a 
Leica VT1000S vibratome. Sections were stored in 1X PBS (1.37M NaCl, 27mM KCl, 
100mM Na2HPO4, 18mM KH2PO4) containing 0.01% sodium azide at 4
o 
C until 
immunostaining. 
 
Antibody Staining  
Sciatic nerve sections were grouped so that one section from each treatment condition was 
incubated with a given antibody solution.  Individual sections were stained with antibodies 
recognizing α-tubulin, acetylated tubulin, EB1, or S100B (a Schwann cell-specific marker). 
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All sections were also stained with anti-phosphoneurofilament and anti-myelin basic protein 
as internal controls and in order to identify regions of interest (for example, neuronal cells).  
Free-floating sections were incubated in PBT blocking agent (1X PBS, 0.1% TritonX-100, 
1% BSA, 1% donkey serum) overnight at 4°C.  Sections were then incubated with primary 
antibodies for 7 days at 4°C with agitation to promote antibody penetration.  Primary 
antibody dilution solutions were removed and sections washed 3 times with PBT at room 
temperature (8 minutes/wash).  Sections were next incubated with secondary antibodies for 2 
days at 4°C with agitation and protected from light. Secondary antibody dilutions were 
removed and sections washed as described above.  Sections were then mounted on glass 
slides using ProLong Gold mounting media with DAPI (Life Technologies P36935) so that 
each slide contained one section from each of the five treatments (paclitaxel, ixabepilone, 
eribulin, and their respective vehicles, Figure S1) that were all stained simultaneously with 
the same antibody solution.  Slides were sealed with nail polish and stored at 4°C in the dark 
until imaging. 
 
Fluorescence microscopy 
Images were collected using an Olympus Fluoview 1000 Spectral confocal system equipped 
with 405nm, 488nm, 559nm, and 635nm laser lines.  Each slide containing one section from 
each of the 4 treatments and incubated in the same antibody solution was imaged with the 
same exposure settings, determined by identifying the brightest-fluorescing section on each 
slide. 20 μm sample depths from each nerve were imaged by sequential laser scanning using 
a 0.5μm step size with an Olympus PLANAPOSC 60x (1.40 NA) high refractive index oil 
immersion objective. 
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Image Analysis 
Images from each slide were imported into Imaris Version 7.5.2 (Bitplane, Zurich, 
Switzerland) and rendered into three dimensional maximum intensity z-stack projections for 
analysis.  To assess changes in gross morphological structure the nuclei, myelin and axons 
were identified using the DAPI, anti-myelin basic protein and anti-phosphoneurofilament 
channels, respectively.  Using the Imaris software surfaces tool, we identified nuclei, myelin 
sheaths and axons based on the fluorescent signal from their appropriate antibody or stain, 
manually thresholding signal-to-background ratio.  To maintain consistency in object 
identification in similarly treated samples, one set of threshold parameters was applied to all 
sections stained with the same antibody solutions and imaged with the same microscope 
settings. Signs of axon degeneration, defined as solid, circular regions of myelin lacking a 
phosphoneurofilament signal, were identified and counted manually and expressed as a 
percentage of total phosphoneurofilament-positive objects present within the nerve bundle.  
For axon area density (defined as the number of objects per μm2 in a 2 dimensional image) 
and nuclei measurements, the 41-image 3D stack was flattened to a 2D image in Fiji using 
the maximum intensity setting.  The number of axons per region of interest (defined by 
phosphoneurofilament signal) or nuclei (defined by DAPI) was quantified using Imaris.  The 
region of interest was manually defined by manually drawing around the edge of each nerve 
bundle with the cursor, referred to as “masking.”  The masked area of this region was 
recorded and only axons or nuclei within this area were included for analysis and calculation 
of frequency of myelin abnormalities.  The number of axons or nuclei was normalized to a 
10
4
um
2
 masked area. 
In order to quantify fluorescence intensity changes, fluorescence values were collected and 
normalized within each slide first, before comparisons were made between slides. 
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Normalization of axonal Cy2 fluorescence signals (depicted in Supplementary Figure S1) 
was accomplished by first identifying the axonal region using the anti-phosphoneurofilament 
(PNF) signal to mask the axon regions specifically differentiating axons from surrounding 
Schwann cells or other cell types present.  The raw values of Cy2 fluorescence were 
determined for each axonal region within the field of view.  The mean Cy2 signal per axon 
was calculated for each treatment to give the “treatment mean.” These values were 
normalized by dividing each treatment mean by the sum of all four treatment means per 
slide.  This method was employed in order to retain the natural variability seen in vehicle 
treatments.  This was the same methodology used previously (Benbow et al. 2016).  The fold 
change values were calculated by first taking an average of the percent fluorescent per axon 
values for each treatment at each timepoint (n = 3-5), then dividing the drug average value 
by its respective vehicle average value. 
 
Statistical Analysis 
Sciatic nerve tissue from three mice for each treatment was analyzed.  For axon area density, 
myelin abnormalities, and nuclei analyses a Student’s T-test was used to compare values for 
each treatment and its vehicle control at each recovery time point.  For fluorescence intensity 
comparisons, a one-way ANOVA with post-hoc Tukey’s tests was employed to test the 
statistical significance between the means of treatment groups separately for each time point.  
In all cases the statistical significance values were set at: *p<0.05, **p<0.01, ***p<0.001. 
 
Results 
Paclitaxel-treated animals exhibit a persistent reduction in axon area density over the entire 
6 month recovery period, unlike ixabepilone- or eribulin-treated animals 
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To investigate the recovery from MTA-induced CIPN, we compared sciatic nerve tissue 
from mice allowed to recover for two weeks, three months, or six months after induction of 
neuropathy via an initial 2 week maximum tolerated dosing schedule (dosing on days 1, 3, 5, 
8, 10, 12) with either paclitaxel (30 mg/kg), ixabepilone (2 mg/kg), eribulin (1.25 mg/kg), or 
their respective vehicles.  We first sought to determine the extent to which the deficits in 
axon area density we previously observed at the onset of neuropathy persist over the 
recovery period.  In our previous work, we determined that two weeks of paclitaxel 
treatment induced a 30% loss of axon area density while eribulin treatment induced a milder 
21% reduction (Benbow et al. 2016).  Subsequent work revealed a similar 20% reduction 
induced by treatment with ixabepilone.  To address the question of the relative recovery 
potential for each drug, we first quantified axon area density over a 6 month period of 
recovery for mice treated with either paclitaxel, ixabepilone, eribulin, or their corresponding 
vehicles in our usual 2-week MTD regimen, defining axons as regions positive for anti-
phosphoneurofilament (PNF) signal in sciatic nerve cross sections (Figure 1A).  Our analysis 
was performed on sciatic nerve tissue from the mid-thigh region, where the nerve is 
composed of about 6% motor, 71% sensory, and 23% unmyelinated sympathetic axons (% 
total number of axons present) (Schmalbruch 1986).  After two weeks of recovery, 
paclitaxel-treated sciatic nerves exhibited a persistent reduction in axon area density of 188 
± 12 axons per 10
4
 μm2 compared to 250 ± 19 axons per 104 μm2 for control (mean ± SEM, 
p<0.05; Figure 1B).  After 3 months of recovery, paclitaxel-treated sciatic nerves exhibited 
additional axonal loss to 174 ± 13 axons per 10
4
 μm2 compared to 213 ± 17 for its vehicle 
control.  After 6 months of recovery, animals began recovering from paclitaxel-induced 
axonal loss, but had not completely recovered to numbers similar to control (223 ± 15 for 
paclitaxel vs. 256 ± 21 axons per 10
4
 μm2 for control).  In contrast, while eribulin-treated 
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mice did exhibit a significant loss of axon density at the end of the 2-week MTD treatment, 
2 weeks of subsequent recovery time resulted in 221 ± 11 axons per 10
4
 μm2 compared to 
214 ± 11 axons per 10
4
 μm2 for control indicating a recovery from the initial effects present 
immediately after dosing. Subsequent time points continued to show similarity between the 
eribulin-treated and vehicle-treated axon area densities, demonstrating the stability of the 
recovery process. Finally, ixabepilone treatment did not induce any significant change in 
axon area density, either at the end of the 2-week MTD treatment or at any subsequent time 
point during the recovery period (221 ± 11 axons per 10
4
 μm2 compared to 275 ± 26 axons 
per 10
4
 μm2 for control at recovery day 1, p = 0.09). 
 
The abundance of myelin abnormalities rapidly declines after cessation of MTA treatment in 
paclitaxe-l, ixabepilone-, and eribulin-treated animals 
Myelin basic protein (MBP) is a major component of the insulating myelin sheath that 
peripheral glia provide to axons which is essential for proper preservation of nerve 
conduction velocity and amplitude across long distances in peripheral neurons.  We 
examined the extent to which signs of axon degeneration and myelin abnormalities persisted 
over the recovery period using immunofluorescence microscopy with an anti-MBP antibody 
(Figure 2A).  A sign of axon degeneration was defined as a fiber structure with a collapsed 
MBP signal and a severely reduced or absent PNF signal. Similar degenerative events have 
been described in several instances of neuronal toxicity and injury, where the space normally 
occupied by the axon is lost and has been replaced by myelin (Muguruma et al. 2006; 
Schnaar et al. 2014; Wozniak et al. 2011).   
The frequency of myelin abnormalities in paclitaxel-, ixabepilone- and eribulin-treated 
animals declined rapidly from their maximum levels observed at the end of their 2-week 
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MTD treatments (6.6%, 0.8% and 2.2%, of total axons, respectively).  Significant residual 
effects on myelin were still present after 2 weeks of recovery from paclitaxel and eribulin 
treatment (0.82% and 0.64% of total axons, respectively), but not for ixabepilone (Figure 
2B). This is likely a consequence of the fact that paclitaxel induced by far the greatest 
abundance of myelin abnormalities. After three months of recovery the frequency of myelin 
abnormalities present in paclitaxel-, ixabepilone- or eribulin-treated nerves had recovered to 
values similar to control. 
 
Paclitaxel- and ixabepilone- but not eribulin-treated animals exhibited increased Schwann 
cell numbers during the post-MTD treatment recovery period 
The neuronal cell bodies for peripheral nerve axons that innervate the extremities reside 
in the dorsal root ganglia adjacent to the spinal column, far from the region of nerve imaged 
in this study.  Therefore, all nuclei in our images are non-neuronal.  We quantified the 
population of non-neuronal nuclei present in sciatic nerve cross sections by counting the 
number of DAPI objects identified by Imaris analyses (Figure 3A).  Our previous work 
demonstrated that paclitaxel treatment but not eribulin treatment led to an increase in the 
number of DAPI-positive structures in sciatic nerves (Benbow et al 2016).  After two weeks 
of recovery, paclitaxel-treated nerves maintained a significantly higher average number of 
non-neuronal nuclei of 41 ± 2.2 per 10
4
 μm2 compared to 26 ± 2.3 per 104 μm2  in the control 
(Figure 3B, *p<0.05).  Interestingly, this increase persisted in paclitaxel-treated nerves even 
after six months of recovery (40 ± 3.5 per 10
4
 μm2  compared to vehicle control 24 ± 4.3 per 
10
4
 μm2).  In contrast, exposure to ixabepilone results in a statistically significant increase 
after two weeks of recovery, then subsided to control levels at the 3 and 6 month time points. 
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Finally, there was no significant difference in the average number of nuclei present in 
eribulin-treated nerves at any time during the recovery period. 
We next sought to identify the additional non-neuronal nuclei in paclitaxel-treated 
nerves.  We hypothesized that due to the fiber disruption in paclitaxel-treated nerves the 
additional nuclei might be additional Schwann cells since these cells are known to 
dedifferentiate and proliferate in order to provide a suitable environment for regeneration 
following nerve injury (Scherer and Salzer 2001, Ceci et al. 2014).  In support of this 
hypothesis, all additional non-neuronal nuclei in paclitaxel-treated nerves were positive for 
both Schwann cell markers S100B (Figure 4) and GFAP (data not shown) at all recovery 
time points. 
 
MTD-induced levels of tubulin, acetylated tubulin and EB1 rapidly return to control levels 
following cessation of drug treatment 
We previously determined the α-tubulin composition in paclitaxel- and eribulin-
treated sciatic nerves at the onset of neuropathy and reported that both drugs increased the 
abundance of axonal α-tubulin 1.9- and 2.6-fold, respectively (Benbow et al. 2016).  A 
parallel analysis of ixabepilone treatment revealed almost no change in α-tubulin level.  
Surprisingly, after two weeks of recovery the levels of α-tubulin quickly returned to control 
levels for both paclitaxel- and eribulin-treated mice and was maintained at that level 
throughout the recovery period (Figure 5A, B, C).  Ixabepilone did not induce any changes 
in -tubulin abundance at any time point during the recovery period. 
Next we assessed changes in tubulin acetylation, a marker of long-lived and stable 
microtubules over the course of recovery.  We previously determined the levels of axonal 
tubulin acetylation in paclitaxel- and eribulin-treated sciatic nerves at the onset of 
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neuropathy and reported that both drugs increased the tubulin acetylation, by 4.6- and 11.7-
fold, respectively (Benbow 2016).  Acetylated tubulin levels declined from maximum levels 
determined during onset, but remained significantly elevated 1.6-fold for paclitaxel (20.49 ± 
1.11 vs. vehicle control 12.33 ± 0.40 relative fluorescence units per axon, Figure 6A, B, C) 
whereas with eribulin acetylated tubulin levels had completely returned to control levels 
from its initial ~11.7-fold increase following two weeks of recovery.  Parallel analyses of 
ixabepilone-treated mice revealed no changes in the abundance of acetylated -tubulin at 
any time point during the recovery period. 
To assess the state of microtubule dynamicity during the recovery period, we next 
quantified the axonal levels of microtubule end binding protein 1 (EB1), a highly conserved 
microtubule associated protein that selectively tracks with the plus ends of growing 
microtubules (Akhmanova and Steinmetz 2008; Jiang and Akhmanova 2011; Jimenez-
Mateos et al. 2005; Moughamian et al. 2013).  We previously determined the levels of EB1 
in paclitaxel- and eribulin-treated sciatic nerves at the onset of neuropathy and reported that 
only eribulin, and not paclitaxel, increased the abundance of axonal EB1 by ~2.2-fold 
compared to its vehicle control.  EB1 levels in eribulin-treated nerves declined rapidly from 
maximum levels at the end of the MTD treatment, returning to control levels after only two 
weeks of recovery (Figure 7A, B, C).  Again, and consistent with the other proteins 
analyzed, ixabepilone did not induce any changes in EB1 abundance at any time point during 
the recovery period. 
 
Discussion 
The mechanisms responsible for regulating the onset and resolution of CIPN remain 
poorly understood.  Here, we sought to test the hypothesis that the differences among MTA 
  80 
mechanism of action underlie their variation in clinical CIPN onset and recovery.  Prior to 
this work, we characterized the initial effects upon sciatic nerve axons immediately 
following a two week maximum tolerated dose (MTD) treatment model of microtubule-
targeting agent (MTA)-induced peripheral neuropathy (Benbow 2016).  To expand this 
work, we report here a timeline of resolution from these initial effects during a six month 
recovery period. 
We found that paclitaxel produced longer-lasting morphological changes in sciatic 
nerves (in axon area density, frequency of myelin abnormalities, and number of Schwann 
cell nuclei) as compared with eribulin and ixabepilone.  Interestingly, with eribulin and 
paclitaxel, many of the substantial biochemical changes in microtubule biochemistry 
previously observed at the onset of neuropathy quickly resolved to control levels after two 
weeks of recovery.  Acetylated α-tubulin remained elevated with paclitaxel after two weeks 
of recovery whereas eribulin had completely recovered from its ~12-fold increase at the 
onset of neuropathy.  In addition, we identified a novel effect of paclitaxel to stimulate and 
sustain the number of Schwann cells.  Therefore, it appears that persistence of drug-induced 
morphological effects after long-term MTA treatment characterizes recovery from CIPN 
while changes in protein abundance are relatively transient.    Understanding these changes 
are initial steps toward identifying the mechanisms responsible for the onset and resolution 
of CIPN. 
 
Paclitaxel induces severe and long-lasting changes to sciatic nerves 
The morphological assessments of sciatic nerve injury demonstrate a uniquely severe 
effect of paclitaxel, with reduced axon area density, increased signs of myelin abnormalities, 
and increases in Schwann cell abundance observed most frequently after paclitaxel 
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treatment. Ixabepilone, which also has notable electrophysiological effects, also produced 
some signs of structural change, but the effects were in general milder than those caused by 
paclitaxel and recovery was more rapid. In general, eribulin caused few, if any, degenerative 
effects, other than early signs of myelin structure disruption. 
Paclitaxel’s induction of Schwann cells at all time points during the recovery phase is 
consistent with the notion that it generates the most cellular damage.  Schwann cells are 
crucial for the proper function and maintenance of peripheral nerves.  These cells are 
responsible for encapsulating axons with a myelin-rich sheath that preserves action 
potentials originating in distal sensory termini and are intimately involved in the 
regeneration process after nerve injury (Lehmann and Hoke 2010, Fu et al. 1997).  
Remarkably, paclitaxel-treated animals continue to exhibit increased levels of Schwann cells 
following 6 months of recovery whereas eribulin-treated animals showed no change and 
ixabepilone-treated animals had a brief increase at two weeks followed by recovery at 3 
months.  Paclitaxel may be unique in inducing Schwann cell proliferation due to its more 
significantly deleterious initial effects on axon area density and abundance of myelin 
abnormalities as compared with ixabepilone or eribulin.  
 
Tubulin composition and biochemistry rapidly returns to control levels 
 Our previous work demonstrated that eribulin and (to a lesser extent) paclitaxel both 
induced levels of acetylated α-tubulin in sciatic nerve axons (Benbow et al. 2016). In the 
present study, axonal levels of acetylated α-tubulin rapidly returned to control levels for both 
drugs during the recovery period.  Interestingly, EB1 is known to co-immunoprecipitate with 
the tubulin deacetylating enzyme HDAC6, indicating a possible regulatory link between 
microtubule acetylation and binding of end-binding proteins (Zilberman et al. 2009).  
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Further, eribulin’s initial increase in α-tubulin acetylation in microtubule networks may 
rescue axonal transport deficits by increasing recruitment of kinesin-1 to microtubules (Reed 
et al. 2006, Bulinski et al. 2006).  Taken together, the presence of beneficial biochemical 
changes during eribulin treatment may create an environment that more easily supports the 
regeneration of damaged nerve fibers when the drug is removed. 
Our previous work demonstrated that eribulin but not paclitaxel treatment induced 
the level of EB1 expression in sciatic nerve axons. During the recovery period, axonal levels 
of EB1 rapidly return to the control level in the eribulin group.  Recent studies in 
differentiated neuronal SK-N-SH cells revealed that the normal comet-tail distribution of 
EB1 on microtubule plus tips is perturbed after paclitaxel treatment, suggesting that 
disruption of microtubule dynamics is a key event in paclitaxel-induced neurotoxicity 
(Rovini et al. 2010). 
 
Long-term retention of paclitaxel in sciatic nerve 
In contrast to their rapid clearance from plasma, paclitaxel, ixabepilone, and eribulin 
enter and are retained in sciatic nerve tissue at vastly different rates (Wozniak et al. 2011). 
Recent pharmacokinetic studies demonstrated that the tissue penetration index (a measure of 
how likely the drug is to enter the tissue) of the sciatic nerve was 30 times higher for eribulin 
than that of paclitaxel, indicating that more eribulin enters the sciatic than paclitaxel 
(Wozniak et al. 2016).  Despite the increased relative uptake of erublin, the observed 
functional impairment and degenerative pathologic changes in dorsal root ganglia and sciatic 
nerves are consistently more severe with paclitaxel (Wozniak et al. 2011).  The relative 
retention also differed greatly between these two drugs.  Mass spectroscopic analysis of 
peripheral nervous tissue 26 days after the first dose of a 2 week MTD schedule (recovery 
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day 12 of this work) revealed that only a small fraction of the maximum level of eribulin 
detected in the sciatic nerve remained (Wozniak et al. 2016).  In contrast, a significant 
amount of paclitaxel was still detectable in sciatic nerves at 26 days.  While the absolute 
amount pf paclitaxel falls over time, the residual drug is likely tightly bound to microtubules 
causing persistent disruption of function and delaying recovery.  These data are consistent 
with a model in which the delayed recovery of paclitaxel-treated nerves may be due to 
accumulation of the drug in nerve tissue after repeated doses.  In support of this model, a 
cumulative dose of paclitaxel is the critical metric for clinical neuropathy risk (Gornstein et 
al. 2014).  Taken together, these data suggest that the incidence and recovery of neuropathy 
may not be correlated with the level of initial uptake, but may instead depend on the 
retention time of each drug in nervous tissue.  We suggest that the sustained morphological 
changes observed in paclitaxel-treated animals are occurring as a result of long-term drug 
retention  which at least in part regulates the resolution of neuropathy. 
 
The first-line drug paclitaxel induces the most severe and longest lasting deleterious effects 
The goal of the current work was to investigate the molecular mechanisms involved in 
regulating the onset and resolution of MTA-induced peripheral neuropathy.  To accomplish 
this goal, we  treated naïve mice (without pre-existing neuropathy) with maximum tolerated 
doses of paclitaxel, ixabepilone, and eribulin to compare their relative induction of 
morphological and biochemical changes.  Clinical treatment with MTAs often involves 
sequential treatment with the drugs investigated here.  For example, paclitaxel is commonly 
used as a first line cancer therapy until drug resistance develops, which then may require 
treatment with a second line drug such as ixabepilone.  If a second line therapy fails, a third 
line therapy may be administered, such as eribulin.  In this clinical setting, eribulin is 
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associated with a relatively low incidence of neuropathy as compared with paclitaxel and 
ixabepilone (Jain and Vahdat 2011, Swami et al. 2012, Vahdat et al 2009).  Our data 
presented here provide a molecular rationale for the more rapid clinical onset and longer 
persistence of paclitaxel-induced neuropathy as compared with eribulin-induced neuropathy. 
However, it should be appreciated that patients who receive second and third line therapies 
most likely begin these additionally therapies with pre-existing neuropathy.  Recent work 
demonstrated that eribulin administered to mice with pre-existing paclitaxel-induced 
peripheral neuropathy had limited additional deleterious effects whereas a second regimen of 
paclitaxel caused additional nerve conduction and amplitude effects (Wozniak 2013).  Our 
preclinical findings raise the possibility that peripheral neuropathy during chemotherapy 
with microtubule targeting agents might be more efficiently managed by optimizing the 
sequential administration of drugs with respect to their severity and potential reversibility of 
neuropathy. 
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Figures 
 
Figure 1. Persistent reductions in axon area density were most severe following paclitaxel treatment, 
with ixabepilone and eribulin showing mild effects.  A, Representative immunofluorescent images of sciatic 
nerve axons during recovery from paclitaxel, ixabepilone, eribulin or vehicle paclitaxel/ixabepilone treatment.  
As there was no statistical difference between the respective vehicles for paclitaxel/ixabepilone and vehicle 
eribulin at any time point, only the vehicle for paclitaxel/ixabepilone is shown in the representative images 
panel.  Axons were identified by phosphoneurofilament (PNF) signal (white).  The area of the nerve bundle was 
traced and measured in Imaris so that only PNF-stained objects within that area were quantified.  Each image 
panel represents 10
4 
um
2
. B, Quantification of axons per 10
4
 μm2  over the recovery period measured from 
images show in A; (n = 5-28 images analyzed per condition); Student’s T-test were performed against the 
vehicle control for each drug at each timepoint, *p < 0.05, **p < 0.01, scale bar = 20μm. 
  
  86 
 
Figure 2. Myelin abnormalities persist in paclitaxel-treated animals, but are resolved after eribulin or 
ixabepilone by day 14.  A, Representative immunofluorescent images of sciatic nerve myelin sheaths during 
recovery from paclitaxel, ixabepilone, eribulin or vehicle treatment. As there was no statistical difference 
between the respective vehicles for paclitaxel/ixabepilone and vehicle eribulin at any time point, only the 
vehicle for paclitaxel/ixabepilone is shown in the representative images panel.  Signs of myelin abnormalities 
were present in all drug-treated animals, but were consistently most severe in paclitaxel-treated mice. B, 
Quantification of nerve fiber collapses per total number of anti-myelin basic protein (MBP, white) stained 
objects. Collapses were defined as fragmented and/or contracted myelin sheaths coupled with a loss of PNF 
protein signal from the associated axons. Red arrowheads indicate myelin sheath collapses. (n = 3-5 images 
analyzed per condition); Student’s T-test was performed against the vehicle control for each drug at each 
timepoint, **p < 0.01, ***p < 0.001, scale bar = 20μm. 
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Figure 3. Paclitaxel increases Schwann cell abundance at all recovery timepoints while ixabepilone 
induced only at day 14 and eribulin showed no effect. A, Representative immunofluorescent images of 
Schwann cell nuclei and myelin sheaths during recovery from paclitaxel, ixabepilone, eribulin or vehicle 
treatment. As there was no statistical difference between the respective vehicles for paclitaxel/ixabepilone and 
vehicle eribulin at any time point, only the vehicle for paclitaxel/ixabepilone is shown.  Values for actual 
respective vehicles were used for the graphs and statistics in B.  B, Quantification of Schwann cell nuclei 
abundance during recovery as detected by DAPI (white). The myelin sheath (MBP, red) is also shown to 
indicate the location of axons.  Scale bar = 20μm.  Student’s T-test was performed against the vehicle control 
for each drug at each timepoint, (n = 3-5 images analyzed per condition), *p < 0.05, **p < 0.01. 
  88 
 
Figure 4. Additional DAPI-positive nuclei are positive for Schwann cell marker S100B at 14 days in 
paclitaxel-, ixabepilone-, and eribulin-treated nerves. Representative immunofluorescent images of one field 
of view of sciatic nerve tissue from each drug- or vehicle-treated animal .  The DAPI/MBP column shows 
DAPI in white and myelin basic protein (MBP) in red, the S100B column shows only the S100B signal (green) 
from the same field of view, the DAPI column shows only the DAPI signal (white), the S100B from DAPI is 
only the S100B signal that colocalizes to the 3-dimensional volume of the DAPI channel, and the secondary 
only column shows the background signal of a section from each treatment processed using the same conditions 
and imaged using the same settings but omitting the primary anti-S100B antibody, indicating limited non-
specific signal from the secondary antibody. As there was no difference between the respective vehicles for 
paclitaxel/ixabepilone and vehicle eribulin at any time point, only the vehicle for paclitaxel/ixabepilone is 
shown.  All additional nuclei were positive for S100B in all treatments at all timepoints tested (data not shown). 
Scale bar = 20μm. 
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Figure 5. Axonal levels of α-tubulin rapidly return to control levels in paclitaxel- and eribulin-treated 
animals, with ixabepilone showing no change at any timepoint. A, Representative immunofluorescent 
images of α-tubulin protein abundance during recovery from paclitaxel, ixabepilone, eribulin or vehicle 
treatment. The phosphoneurofilament column (PNF) shows only the axons.  The alpha-tubulin column shows 
only the total alpha tubulin signal of the same field of view.  The merge column shows the overlay of alpha 
tubulin (green) and PNF (yellow) signals.  As there was no statistical difference between the respective vehicles 
for paclitaxel/ixabepilone and vehicle eribulin at any time point, only the vehicle for paclitaxel/ixabepilone is 
shown.  Values for actual respective vehicles were used for the graphs and statistics in B and C.  B, 
Quantification of axonal α-tubulin levels in drug and vehicle-treated sciatic nerves following 1, 14, or 90 days 
of recovery.  C, Recovery of fold change in axonal α-tubulin abundance from respective vehicle.  The 
horizontal gray line in C indicates a fold change of 1, or no difference from the vehicle control.  Statistics: 1-
way ANOVA with Tukey post-test, ***p < 0.001, (n = 3-5 images analyzed per condition).  Scale bar = 20μm.
  90 
 
Figure 6. Increased axonal levels of acetylated α-tubulin persist in paclitaxel-treated animals while 
eribulin-treated animals rapidly recover to levels similar to control at day 14, and ixabepilone showing 
no change from its vehicle control at any timepoint.  A, Representative immunofluorescent images of 
acetylated α-tubulin protein abundance during recovery from paclitaxel, ixabepilone, eribulin or vehicle 
treatment. The phosphoneurofilament column (PNF) shows only the axons.  The acetylated alpha-tubulin 
column shows only the total acetylated alpha-tubulin signal of the same field of view.  The merge column 
shows the overlay of acetylated alpha-tubulin (green) and PNF (yellow) signals. As there was no statistical 
difference between the respective vehicles for paclitaxel/ixabepilone and vehicle eribulin at any time point, 
only the vehicle for paclitaxel/ixabepilone is shown.  Values for actual respective vehicles were used for the 
graphs and statistics in B and C.  B, Quantification of axonal acetylated axonal α-tubulin levels in drug and 
vehicle-treated sciatic nerves following 1, 14, or 90 days of recovery C, Recovery of fold change in axonal α-
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tubulin abundance from respective vehicle.  The horizontal gray line in C indicates a fold change of 1, or no 
difference from the vehicle control. Statistics: 1-way ANOVA with Tukey post-test, *p < 0.05, **p < 0.01, 
***p < 0.001, (n = 3-5 images analyzed per condition).  Scale bar = 20μm. 
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Figure 7. Axonal levels of EB1rapidly return to control levels in eribulin-treated animals, with paclitaxel 
and ixabepilone showing no change at any timepoint. A, Representative immunofluorescent images of 
axonal end binding protein 1 (EB1) abundance during recovery from paclitaxel, ixabepilone, eribulin or vehicle 
treatment. The phosphoneurofilament column (PNF) shows only the axons.  The acetylated alpha-tubulin 
column shows only the total EB1 signal of the same field of view.  The merge column shows the overlay of 
EB1 (green) and PNF (yellow) signals. As there was no statistical difference between the respective vehicles 
for paclitaxel/ixabepilone and vehicle eribulin at any time point, only the vehicle for paclitaxel/ixabepilone is 
shown.  Values for actual respective vehicles were used for the graphs and statistics in B and C.  B, 
Quantification of axonal EB1 levels in drug and vehicle-treated sciatic nerves following 1, 14, or 90 days of 
recovery. C, Recovery of fold change in axonal EB1 from respective vehicle.  The horizontal gray line 
indicates a fold change of 1, or no difference from the vehicle control.  Statistics: 1-way ANOVA with Tukey 
post-test, ***p < 0.001, (n = 3-5 images analyzed per condition).  Scale bar = 20μm.
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Supplemental Figure S1 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Figure S1. Normalization of Cy2 fluorescent signal.  A. Representative sections from one 
nerve per 5 treatment groups, stained with same antibody solution and imaged using same microscope settings. 
Axonal (3D) region was identified by phosphoneurofilament (PNF, yellow in fluorescent images), then Cy2 
(green) inside delimited regions were quantified. B. The Cy2 fluorescence value identified per axon is 
represented by the green boxes.  All axons per treatment were averaged to give the treatment mean. The 
treatment means were then normalized by dividing each treatment mean but the sum of treatment means 
observed on the slide, each normalized value was multiplied by 100, to be represented as a percent of total 
fluorescence observed.  This was repeated twice per nerve for each of 3-5 nerves per treatment to obtain a 
nerve value.  The mean of the 3-5 nerve values is represented in the graphs in main figures. VehPac/Ixa = 
Vehicle for Paclitaxel and Ixabepilone, VehErib = Vehicle for Eribulin, Pacli/Pac = Paclitaxel, Ixa = 
Ixabepilone, Erib = Eribulin. 
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Chapter IV. Digital Quantification of Neurite Outgrowth and Retraction by Phase 
Contrast Microscopy: a tau Perspective 
 
Summary 
The proper organization and function of the mammalian nervous system relies on 
neuronal processes or “neurites”, extended morphological projections that include axons and 
dendrites. Tau is a structural microtubule-associated protein that is widely expressed in the 
nervous system that mediates the establishment of cell polarity, neurite outgrowth, and 
axonal transport. A useful model for studying the establishment and maintenance of these 
neuronal structures are rat neuronal PC12 cells, which can be induced to express tau and 
project neurites by treating the cells with nerve growth factor (NGF). Here, we present a 
simple method for continuously measuring the rate of neurite outgrowth and retraction over 
time by neurite length and neurite area analyses. This method uses freely available ImageJ 
software and widely available phase contrast imaging. 
 
Introduction 
The microtubule-associated protein tau is an essential protein that promotes the 
highly specialized morphologies in the nervous system and has important roles in cell 
differentiation and polarization. Primarily an axonal protein in mature neurons (in contrast to 
the dendritic MAP2), tau promotes the organized stabilization of microtubules and is a key 
regulator of neurite formation during neuronal differentiation (Drubin et al. 1985. As an 
intrinsically disordered protein, tau does not adopt a compact folded structure but rather is 
highly flexible and mobile (Schweers et al. 1994). This flexibility allows tau to stabilize 
microtubules by binding to the MT surface and promoting self-assembly from tubulin 
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subunits (Witman et al. 1976, Gustke et al. 1994). As a result of its effects on microtubule 
biochemistry, tau regulates the rate of neurite elongation and stability (Esmaeli-Azad, 
McCarty, Feinstein 1994, Butner and Kirschner 1991, Drubin et al. 1985). Axon outgrowth 
is inhibited when tau is suppressed using synthetic antisense oligonucleotides, which 
supports tau’s necessity during axon outgrowth (Caceres and Kosik, 1990). Interestingly, 
when non-neuronal cells are induced to express high levels of tau, they can develop cellular 
processes containing dense arrays of bundled microtubules that are morphologically similar 
to neuronal axons (Baas, Pienkowski, and Kosik, 1991, Chen et al. 1992). Taken together, 
these studies suggest that tau’s primary function is to promote microtubule assembly and 
bundling during neurite outgrowth. 
The rat adrenal pheochromocytoma PC12 cell line has been a useful model for 
studying tau action during neurite outgrowth (Greene andTischler 1976). Upon treatment 
with nerve growth factor (NGF), PC12 cells cease to proliferate and extend branching 
processes similar to those produced by primary neurons in culture (Green and Tischler 1976, 
Drubin et al. 1985). Treatment of PC12 cells with NGF, either alone or together with 
dibutyryl cAMP (dbcAMP), causes a rapid and strong induction of tau expression (Gunning 
et al. 1981). Tau expression is induced within 3-4 days of NGF treatment, coincident with a 
massive increase in microtubule assembly and neurite outgrowth. Upon NGF withdrawal, 
tau is quickly degraded while neurites disappear through retraction and fragmentation 
(Drubin et al, 1985). The ability to induce tau expression through NGF-mediated 
differentiation makes the PC12 line a valuable tool for investigating mechanisms of tau 
biology specifically and axonal homeostasis in general. 
 Here, we present a simple method for digitally quantifying neurite length and neurite 
area during differentiation of PC12 cells by phase contrast imaging. Our methods, which 
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should be generally adaptable to neurite outgrowth studies, take advantage of freely available 
ImageJ plug-ins combined with non-invasive phase contrast imaging to measure neurite 
morphology continuously over time.  The example data presented here specifically applies to 
neurite outgrowth, however this method could also be used to study neurite retraction 
following the application of agents that perturb tau and/or microtubule stability. 
 
Materials: 
 Corning Costar 6-well or 12-well cell culture plates, flat bottom with lid, tissue 
culture treated, nonpyrogenic, polystyrene, sterile, 6-well Cat. 3516, 12-well Cat. 
3513 
 Gibco antibiotic-antimycotic 100X (contains 10,000 units/mL of penicillin, 10,000 
μg/mL of streptomycin, and 25 μg/mL of Gibco Amphotericin B), Thermo Fisher 
Cat. 15240062, store at -20°C 
 Dulbecco’s modified Eagle Medium powder, high glucose, [+] L-glutamine, [+] 
pyridoxine hydrochloride, [+] 110 mg/L sodium pyruvate, [-] sodium bicarbonate, 
Gibco 12800-082, store at 4°C 
 Bovine calf serum, supplemented, HyClone, Cat SH30072.03, Store at -20°C 
 Heat Inactivated (HI) Horse Serum, Gibco, store at -20°C 
 Poly-L-Lysine hydrobromide, Sigma P2636-100mg, in sterile water at 10 µg/mL, 
store at 4°C 
 Sterile pipettes and Pipetteman OR glass Pasteur pipettes with rubber bulb 
 N6,2’-O-dibutyryladenosine 3’,5’-cyclic monophosphate sodium salt (dbcAMP), 
Sigma D0260-100 mg.  Make a stock solution of 250 mM in sterile DMSO, store 
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20uL aliquots at -20°C.  The final concentration is 0.5 mM (1:500 dilution from 
stock) 
 Nerve Growth Factor (NGF)-2.5S from murine submaxillary gland, lyophilized 
powder, suitable for cell culture, Sigma N6009-4X25UG, diluted to 10 µg/mL in 
PC12 complete media, store 20uL aliquots at -20°C 
 Inverted brightfield microscope equipped with phase optics, camera, and 10X 
objective 
 
Methods: 
1. Cell culture and differentiation  
1. Maintain PC12 cells on plastic dishes in Dulbecco’s modified Eagle’s medium, 
supplemented with 5% supplemented calf-serum, 5% horse serum, 3.7 g/L 
NaHCO3, and 1X antibiotic/antimycotic at 37°C and 5% CO2 until 50-75% 
confluent (4-7 days for a 10 cm
2
 dish). 
2. Coat plastic cell culture dishes to be used for neurite outgrowth assays with 10 
μg/mL poly-L-lysine (PLL) in sterile water for at least 1 hour at room 
temperature in a cell culture hood prior to plating cells. 
3. When ready to seed cells, aspirate as much of the PLL solution as possible and 
rinse the surface three times with enough 1X PBS to cover the bottom of the 
well at room temperature, leaving the last wash in the well to prevent drying of 
the surface. With each wash, swirl the plate to collect any un-adhered PLL 
(soluble PLL is toxic to cells).  Set the plate aside while preparing cells. 
4. Remove 80% of the media from the maintenance culture dish and discard. 
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5. Dislodge the cells from the surface of the maintenance culture dish by spraying 
the remaining media across the surface of the well using an automatic 
Pipetteman equipped with a 5 mL sterile pipette (alternatively, a Pasteur pipette 
with a rubber bulb can be used). 
6. Triturate the cell suspension by drawing the cell suspension into the pipette and 
forcing it out against the bottom of the dish while holding the pipette opening 
flush against the bottom of the well.  The cells are quite hardy and will not break 
from this treatment. Repeat 10 times until all the cell clumps are dissociated.   
7. Determine the cell density using a hemocytometer.  No tryphan blue is required 
if counting is done using a phase contrast microscope. 
8. Based upon the cell density, calculate the volume of cell suspension to add to 
fresh media so that the final cell density will be 1-5 x 10
3
 cells per cm
2
 of total 
surface area of either 6- or 12-well cell culture plates. 
9. Add an appropriate volume of the cell suspension to the total volume of media 
needed for seeding all dishes or wells. 
10. Invert the diluted cell suspension tube 5 times to homogenize the suspension. 
11. Aspirate the PBS wash from each well of the PLL coated plate and immediately 
add the appropriate amount of diluted cell suspension to each well. 
12. Return plate to incubator at 37°C and 5% CO2 for 1-3 hours to allow cells to 
adhere to the surface. 
13. After 1-3 hours, apply dbcAMP in DMSO to 0.5 mM final concentration to each 
well from a 250 mM stock solution in DMSO.  This serves to initiate rapid 
neurite outgrowth. 
14. Return the plate to the incubator at 37°C and 5% CO2 for 24 hours. 
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15. After 24 hours, add β-NGF (dissolved in complete PC12 media) to a final 
concentration of 10-50 ng/mL to each well. 
16. Spike the media in each well every other day with NGF for the duration of the 
differentiation process (Figure 1A). 
17. On day 5, perform a half media change and supply fresh NGF. 
18. If media begins to become acidic (orange color), perform a complete media 
change and supply fresh NGF. 
19. Cells are considered fully differentiated after 7 days of NGF treatment (8 total 
days of differentiation). Cells should be imaged each day of the time course for 
subsequent analysis (detailed below). 
 
Notes: 
 It is essential that cells are plated at a density that is low enough for neurites to be 
able to project without contacting other cells or neurites early in the time course. If 
neurites encounter other neurites, they will stop their outgrowth and this will bias 
neurite outgrowth measurements. 
 Cell dissociation can be monitored under a microscope. If cells are still significantly 
clumped when plated for differentiation, increase the number of trituration cycles to 
get as close to single cells as possible. 
 Add NGF to each well in a sufficiently large volume of complete media to minimize 
pipetting error. The rate of neurite outgrowth is sensitive to NGF concentration. 
 If a neurite retraction experiment is performed it is essential to include an appropriate 
negative and/or vehicle control for any experimental condition.  Ideally each multi-
well plate seeded with the same cell dilution should have its own negative control on 
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the same plate.  The negative control allows each multi-well plate to be internally 
controlled for variations in cell seeding density and differentiation efficiency. 
 Store plates being coated with PLL at 4°C overnight if unable to seed the same day.  
Allow the plates to come back to room temperature in a cell culture hood for ~30 
minutes before plating cells, or place in an incubator at 37°C for 10 minutes. 
2. Phase contrast imaging 
1. Be sure the microscope’s condenser is properly aligned for Köhler illumination to 
achieve even illumination of the sample and to provide maximum contrast between 
cell bodies and neurites. To do so, bring the sample into focus under a 10X objective, 
then fully close the field diaphragm so that the edges of the field diaphragm are 
visible while looking through the eyepieces. While continuing to observe the opening 
through the eyepieces, adjust the height of the condenser so that the edges of the field 
diaphragm are sharp and well defined, then adjust the position of the field diaphragm 
opening using the adjustment screws so that is directly centered in the field of view. 
From the fully closed position, slowly open the field diaphragm until the edges of the 
opening are just outside the field of view. 
2. Adjust the microscope’s bulb intensity and camera exposure time so that the 
background is a medium gray and the cell bodies are not overexposed (Figure 1B).  If 
possible, store the acquisition settings for future use. 
3. Adjust the focal plane so that the neurites are in focus. The cell bodies may appear 
slightly out of focus but this will not affect analysis. 
4. Image at least five random fields of view per well of each culture plate (Figure 1B). 
 
Notes: 
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 Even illumination is critical for quantitative phase contrast microscopy. Thus, it is 
very important to minimize background interference and create as much contrast as 
possible between the background and neurites without overexposing the cell bodies. 
This can be achieved by ensuring the condenser is properly adjusted, the field 
diaphragm closed as much as possible, and the exposure properly set to adequately 
expose the cell’s features. 
 The periphery of most culture plate wells tend to have higher background and less 
contrast when using phase contrast. The best contrast can be achieved at or near the 
center of each well. 
 Do not adjust the exposure settings during imaging. This will ensure that the 
background levels are consistent throughout the experiment and will produce higher 
quality neurite area measurements. 
 
3. Neurite length measurements 
1. If the NeuronJ plugin (Meijering 2017) is not already installed in ImageJ, install it by 
downloading the install files to ImageJ’s plugins folder. Restart ImageJ after 
installing. 
2. Once in Image J, open the NeuronJ plugin by selecting “NeuronJ” under the 
“Plugins” drop-down menu. 
3. Open an image using the “Open” function under the “File” drop-down menu (Figure 
2A). 
4. Ensure that the scale is correctly set for the image by selecting “Set Scale” under the 
“Analyze” drop-down menu. Enter the known distance in pixels per micron that 
corresponds to the objective used. This value must be determined for each individual 
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microscope and camera setup using a calibrated slide. In our case the 10X objective 
corresponds to 1.553 pixels/μm. Change the unit of measurements to “μm.” Check 
the “Global” setting to apply this scale to all subsequently loaded images. Select 
“OK” to apply the scaling. 
5. Click on the “Add tracings” button on the menu bar. 
6. For each neurite to be measured (criteria below), click once at the origin of the 
neurite at the cell body and follow along the neurite’s length with the cursor. If the 
automatic detection does not accurately trace the neurite, click along the length of the 
neurite to lock the tracing at certain points along the neurite. When the end of the 
neurite is reached, a double click on the mouse completes the tracing. 
7. When all eligible neurites have been measured within the image, click the “Measure 
Tracings” button on the menu bar to measure the tracings. The individual tracing 
lengths and a summary of all tracings within the image can be copied to a 
spreadsheet or graphing software for analysis. 
8. Save the tracing file to the same directory as the image. When the image is opened 
again within NeuronJ, the tracing file will be loaded automatically (Figure 2B). 
9. Before closing the image, count the number of cell bodies present. Use the “Multi-
point Tool” found on the ImageJ menu bar to click on each cell body and record the 
final count to a spreadsheet. 
 
Notes: 
 Only neurites that originate and terminate in the same field of view should be 
analyzed. Any neurites that enter from outside the image or extend out of the image 
should be omitted from neurite length measurements. 
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 Neurites that cross other neurites should be excluded, as they may be stabilized as a 
result of their interactions.  At the cell densities used here, less than 10% of neurites 
cross one another.  If required, reduce then cell density to prevent neurites crossing 
one another. 
 A good rule of thumb for determining what constitutes a neurite is that a “neurite” is 
at least as long as the diameter of the cell body. 
 Holding the “Shift” key produces a straight line segment that is useful for navigating 
along neurites that may be close together. Inaccurate tracings can be removed by 
using the “Delete tracings” function on the menu bar. 
 The available data in NeuronJ’s measure function includes the length of each 
individual neurite, a sum of all lengths within an image, and mean neurite length. 
 
4. Neurite area measurements 
1. Open ImageJ and load a 10X phase-contrast image file. Ensure that the image is 
scaled correctly as described above. 
2. Open the threshold settings under “Image,” “Adjust,” “Threshold.” 
3. Drag the upper threshold bar to the lower limit so that the number to the right 
displays “0.” Ensure that the “Dark Background” box is selected and “Stack 
Histogram” is not selected (Figure 2C). The neurites should appear black and the 
background white. Drag the lower threshold bar until the background starts to be 
visible (as black), then make small adjustments so that the background is still white. 
The upper limit is typically set slightly to the left of the main peak shown on the 
threshold graph (Figure 2C). Small specks in the background are acceptable and will 
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be filtered out later. The image should be shown as thresholded as in Figure 2D.  
Close the threshold window (do not select “auto” or “apply” from this window). 
4. Select the “Analyze Particles” option under the “Analyze” drop-down menu. 
5. Enter “10-Infinity” in the “Size” box, check the box for “Pixel units,” enter “0.00-
0.40” in the “Circularity” box, then press OK (Figure 2F). 
6. A results dialog will open after “OK” is pressed. Notice which areas were selected in 
the image. If the identified areas are not appropriate, close the results windows 
without saving and adjust the analyze particles size and circularity values until only 
the neurite areas are identified. 
7. Once appropriate particle size and circularity settings are determined that identify 
only neurites, they should be applied to all images in the set without adjustment. 
8. Copy the results for individual particles from the “Results” window and from the 
“Summary” window to a spreadsheet. Repeat steps 1-5 for at least five images per 
condition, making sure to copy the results to a spreadsheet after analyzing each 
image. 
 
Notes: 
 If necessary, remove erroneous regions of interest (ROIs) by right-clicking the entry 
in the results window and selecting “Cut”. Each ROI is numbered for identification. 
The ROIs can also be overlaid onto the original image to verify neurite identification. 
To do so, open the original image again through ImageJ without closing the 
thresholded and analyzed image. Under the “Image” drop-down menu, select the 
“Overlay” menu and select “From ROI Manager” (Figure 2E).  If desired, the ROI’s 
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can be saved for each image by selecting “More” from the ROI Manager and 
selecting “Save.”  Load existing ROIs by selecting “Open” from the same menu. 
 The particle size and circularity settings listed here are given as starting points and 
should be optimized for the level of background in the image (particle size filter) and 
general shape of cell bodies of the neurons being analyzed (circularity filter). A 
larger circularity value will maintain particles that are more round (i.e. cell bodies) 
while a smaller value will maintain more longer and straight particles (neurites).   
 Each image must be manually thresholded and the limits should be similarly set to 
achieve consistent analysis throughout the data set. Thus it is important during image 
acquisition to maintain a consistent background intensity. 
 
5. Data Analysis 
1. The average neurite length from each image (at least five per experimental condition) 
can be calculated in Excel and copied to a data analysis software such as GraphPad 
Prism for statistical analysis (Figure 2G). Using the number of cells per image, the 
average neurite length per cell can be calculated by dividing the sum of neurite 
lengths per image by the number of cells per image. The total neurite length per 
image can be found by taking the sum of all neurite lengths in an image, and the 
average per condition can be calculated by dividing this total by the number of cell 
bodies counted for each image. 
2. The average area per image can be calculated by first adding together all the areas of 
all particles identified in an image and dividing by the number of cells. The sum of 
areas can be calculated by adding together each particle area sum from each of the 5 
images analyzed. 
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3. To normalize area data before comparing across experiments, divide the total neurite 
area of each treatment well by the area of the control well. This value is the “index” 
value or “percent of control.” 
 
Notes: 
 Each plate should be normalized to its own control before comparing values across 
plates so that neurite length and area measurements are internally controlled for 
variations in cell seeding density and growth conditions. Thus it is important to 
include a negative and/or vehicle control on each multi-well plate that is imaged. 
 
Conclusions 
We presented a simple method for digitally quantifying neurite length and area during 
differentiation of PC12 cells. This method allows continuous measurement of neurite 
morphology during neurite outgrowth and can also be applied to neurite degeneration in live 
cells. In principle, this method could be applied in studies involving rates of axon outgrowth 
as well as mechanisms of neurotoxicity resulting from insults to neuronal homeostasis. 
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Figures 
 
Figure 1. PC12 differentiation by nerve growth factor and dbcAMP over eight days in 5% 
HI-horse serum and 5% calf serum-containing media at 37C and 5% CO2. A, Schedule of 
cell culture conditions.  dbcAMP is added three hours post-seeding, then NGF is added to 
existing media 24 hours later and every other day following.  A half media change can be 
performed on day 5 if necessary, but may not be required.  B, Representative 10X phase 
contrast images of PC12 cells corresponding to each day of the schedule shown in A, scale 
bar = 100 μm. 
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Figure 2. Digital quantification of neurite outgrowth in differentiated PC12 neuronal cells. 
A, Representative 10X phase contrast image of Day 8 PC12 cells, scale bar = 100 μm.  B, 
Neurites traced for length measurements (red) in the NeuronJ plugin for ImageJ.  C, 
Threshold settings used for neurite area measurements.  Note the position of the minimum 
and maximum threshold values and “dark background” selection.  D, Thresholded version of 
the original image shown in A.  E, Overlay of the original image and the identified areas 
from the thresholded image (shown in yellow).  F, Analyze particle settings, showing the 
particle size and circularity values.  G, Representative data of neurite length and neurite area 
over eight days of differentiation. Measurements are from five images per timepoint.  From 
left to right, the graphs represent the average length or area of all neurites per image for five 
images, the sum of the total neurite length or area for five images, and the average neurite 
length or area per cell (total value divided by the number of cell bodies in the corresponding 
image).  Bar graphs are mean ± SEM, produced in GraphPad Prism. 
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Chapter 5: Assessment of microtubule-targeting agents’ effects on neurite outgrowth, 
retraction, and on cytosolic α-tubulin acetylation in cultured PC12 cells 
 
Summary 
This chapter describes a progress update on investigations of the cellular and 
molecular mechanisms of MTA-induced neurotoxicity.  Although a great many theories have 
been proposed to explain how inhibition of microtubule dynamics leads to degeneration of 
post-mitotic sensory neurons, the molecular mechanisms responsible for the induction, 
progression, and recovery of CIPN are still unclear.   Here, we analyzed the effects of four 
commonly used microtubule targeting agents on cell proliferation, neurite morphology and 
tubulin biochemistry in neuronal PC12 cells using phase contrast microscopy and 
immunoblotting, respectively.  Treatment with paclitaxel, ixabepilone, vincristine, or 
eribulin induced dose-dependent losses of neurite area, recapitulating the 'dying back' of 
axons observed in clinical CIPN.  IC50s for neurite retraction were 11.9, 11.3, 1.9, and 6.0 
nM for paclitaxel, ixabepilone, vincristine, and eribulin, respectively.  Compound-specific 
effects, such as neurite fragmentation and thinning by eribulin or neurite swelling by 
paclitaxel, were also observed.  Finally, increasing tubulin acetylation, a marker associated 
with microtubule stability, was insufficient to protect cells from drug-induced loss in neurite 
area.  Collectively, these results demonstrate that PC12 neurons are a useful model for 
investigating the molecular mechanisms of CIPN. 
 
Introduction 
Interference with microtubule function is a common therapeutic strategy for treating 
many types of cancers.  The anti-mitotic activity of microtubule-targeting agents (MTAs) is 
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generally accepted to derive from their ability to alter normal regulatory mechanisms 
controlling microtubule dynamics.  Disruption in the diverse functions of microtubules, such 
as chromosome segregation, microtubule-based transport, and cell structure, can lead to 
tumor cell death (Jordan et al. 1995, Jordan and Wilson 2004, Argyriou et al. 2012, Field et 
al. 2014, Porunchynsky et al. 2015).  However, systemic administration of MTAs also 
exposes non-target cells of the nervous system to their action, which in turn can lead to 
severe and dose-limiting neuropathic side effects.  Chemotherapy-induced peripheral 
neuropathy (CIPN) is a dose-dependent sensory neuropathic pain that ranges from numbness 
and tingling to hypersensitivity that originates in distal extremities (fingers and toes) and 
progresses proximally toward the trunk.  The neurons mediating pain in CIPN are post-
mitotic and thus no longer require microtubules for chromosome segregation.  However, the 
axonal microtuble cytoskeleton is essential for structure and transport of messages and 
organelles back and forth from the nucleus.  Therefore, the onset and progression of CIPN 
may result from non-mitotic effects of MTAs on axonal microtubules of peripheral nerves, 
such as through structural changes that alter affinity of microtubule associated proteins. 
The molecular mechanisms involved in regulating MTA induced neurotoxicity 
during chemotherapy are poorly understood.  While the in-vitro mechanisms of action of 
many unique agents have been well characterized in reconstitution experiments, studies 
focusing on the response of whole live neurons to long-term drug treatment are lacking.  The 
rat adrenal pheochromocytoma PC12 cell line has been a useful model for studying neurite 
outgrowth (Greene and Tischler 1976). Upon treatment with nerve growth factor (NGF), 
either alone or together with dibutyryl cAMP (dbcAMP) (Figure 1A), PC12 cells cease to 
proliferate and extend branching processes similar to those produced by primary neurons in 
culture (Green and Tischler 1976, Drubin et al. 1985).  Prior to NGF treatment, PC12 cells 
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continually divide with one cell division occurring about every 48 hours.  Following NGF 
treatment, PC12 cells no longer divide and microtubules are primarily involved in cell 
structure, neurite outgrowth, and molecular transport.  To compare concentrations that arrest 
neurite outgrowth or initiate neurite retraction with concentrations that inhibit cell division, 
we exposed either undifferentiated (mitotic) or differentiated (post-mitotic) PC12 cells to 
either paclitaxel, ixabepilone, vincristine, or eribulin and determined IC50s for cell 
proliferation and neurite retraction, and compared these values with reported IC50s for 
proliferation of various cancer cell lines.  We found that in general, neurite retraction was 
initiated at lower drug concentrations than were required for inhibition of cell proliferation 
in PC12 cells.  Vincristine was the most potent in reducing neurite area, followed by 
eribulin, ixabepilone, and paclitaxel.  By comparing the IC50 for neurite retraction and 
cancer cell proliferation of each agent, we found that neurites were comparatively more 
tolerant of eribulin.  In general, the IC50s for neurite retraction (VCR>ERB>IXA>PTX) did 
not correlate well with the clinical incidence of severe (grades 3/4) clinical neuropathy [VCR 
(31%) > PTX (27%) > IXA (20%)> ERB (7%)].  However, when compared to the IC50s for 
cancer cell inhibition, the ratio of inhibitory concentrations indicates that neurites were more 
tolerant of eribulin treatment than for paclitaxel, vincristine, and ixapilone. 
Our investigations here focused on four commonly used CIPN-inducing MTAs: 
paclitaxel, ixabepilone, vincristine, and eribulin. Previously, our group assessed the 
propensity of each of these agents to induce neuropathy in a 2 week administration, 
maximum tolerated dose mouse model (Benbow et al. 2016).  Biochemically, paclitaxel and 
eribulin both induced α-tubulin expression in mouse sciatic nerves (~1.9 and ~2.5 fold, 
respectively). Given that paclitaxel has been shown to promote microtubule stability (at least 
in short-term cell culture and in vitro biochemical analyses), it was not surprising that 
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paclitaxel treatment resulted in a ~5 fold increase in tubulin acetylation, a well-established 
marker for microtubule stability (Webster and Borisy 1989, Szyk et al. 2014). However, 
given that eribulin has been shown to be a microtubule destabilizer in short-term cell culture 
and in vitro biochemical experiments, it was very surprising to observe that eribulin induced 
tubulin acetylation by ~11 fold in the sciatic nerves.  This unexpected finding led us to 
propose the hypothesis that the positive biochemical effects of eribulin observed in sciatic 
nerves of two week eribulin-treated mice compensated in part for its observed morphological 
deficits (Benbow et al. 2016). 
An increase in acetylated tubulin levels suggests that the microtubule cytoskeleton in 
eribulin-treated nerves is more stable than that of paclitaxel-treated nerves, which could 
account for eribulin’s lower incidence of severe (dose-limiting) neuropathy.  Tubulin 
acetylation has long been used as a marker of microtubule stability (Webster and Borisy 
1985; Szyk et al. 2014). Initially, acetylation was viewed more as a consequence of 
microtubule stability rather than as a promoter of microtubule stability. However, more 
recent work has suggested a more active role in promoting microtubule stabilization. For 
example, increasing tubulin acetylation can rescue dysfunctional axonal transport and 
locomotor deficits in Drosophila (Godena et al. 2014) and can promote recruitment of 
dynein and kinesin-1 to microtubules in vitro and in mammalian cells.  Indeed, inhibition of 
histone deacetylase 6 (the primary tubulin deacetylase) leads to markedly increased levels of 
tubulin acetylation and compensates for the transport deficit in Huntington’s disease 
(Dompierre et al., 2007). Here, to test the hypothesis that increased levels of tubulin 
acetylation can minimize the deleterious effects of MTAs in post-mitotic neurons, we used 
the small molecule tubacin to inhibit HDAC6, thereby increasing tubulin acetylation and 
asked whether the neurites were protected from paclitaxel and eribulin induced neurite loss.  
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We found that this treatment failed to protect neurites from the deleterious effects of both 
paclitaxel and eribulin. 
 
Methods 
Cell culture 
PC12 cells were maintained in DMEM containing 5% horse serum and 5% heat-
inactivated calf serum, 1X pen/strep/fungizone, and 3.7 g/mL sodium bicarbonate.  Prior to 
differentiation, cells were seeded at 3000 cells/cm
2
 (for imaging) or 10,000 cells/cm
2 
(for 
lysates) on plastic tissue culture-treated 12-well and 6-well plates, respectively, that had 
previously been coated with poly-L-lysine (Sigma, 10 µg/mL in sterile water) for at least 1 
hour at room temperature.  Differentiation was initiated 1 hour after seeding by adding 
0.5mM dbcAMP.  24hrs later NGF was added to 20ng/mL, and cells were provided fresh 
NGF every two days and a half media change every 4 days.  Cells were differentiated for 8 
days before drug-treatment in neurite retraction studies, or 5 days before neurite outgrowth 
studies. 
 
Drugs 
Paclitaxel, ixabepilone, vincristine, and eribulin were diluted in DMSO to stock 
concentrations of 1000X (1, 3, 9, 27, or 81µM). All dilutions were thawed on ice until being 
added to cells, and each aliquot was only used once (multiple freeze-thaws were not 
allowed).  Tubacin (Sigma) was diluted to a stock concentration of 10mg/mL in DMSO and 
then diluted to 1000X concentrations in DMSO of 0.2, 0.6, 2, 6, or 10mM for 24hr dose 
response experiments, and used at 6uM final concentration for 24hr pre-treatment 
experiments.  Equal volumes of DMSO were used for all treatments and one set of time-
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matched vehicle controls were included on each plate. The final concentration of DMSO did 
not exceed 0.1%.  Cells were exposed to drugs in duplicate and triplicate wells/concentration 
for biochemistry and microscopy, respectively. 
 
Undifferentiated Cell Viability 
Rat neuronal precursor cells (PC12) were plated at a density of 20,000 cells/cm
2
 and 
exposed to a range of concentrations of each microtubule targeting agent for 48 hours.  Cell 
viability was measured using the live-cell indicator calcein-AM.  Live cells emit green 
fluorescent light which can be detected at 495nm. Using fluorescence microscopy, five 
different images were acquired per well (one in each corner and the center) to account for 
plating variability.  Automated cell counting was performed using custom macros in ImageJ.  
Briefly, images were thresholded and binarized to allow cell identification. To determine the 
IC50 for each MTA, a dose response curve was generated in Graphpad Prism 5 and a 
log(inhibitor) vs. response curve with variable slope was best-fit to the number of live cells 
for each drug over a range of concentrations from 1nM to 243nM. 
 
Neurite Retraction 
To assess neurite morphology, triplicate wells for each condition were imaged by phase 
contrast microscopy.  Five random fields of view from each well were captured with a 10X 
objective using an Olympus IX70 inverted bright field microscope equipped with phase 
contrast optics.  Each image was processed for neurite area measurements in ImageJ using 
the method described in Cook et al. 2017 (see chapter 4).  Briefly, each image was manually 
thresholded to remove the background pixels and cell bodies so that only the neurites 
remained.  Using the analyze particles function in ImageJ with a size and circularity filter, 
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the neurite area was measured.  Data from each plate was normalized to a vehicle control 
value on the same plate before comparing across plates to account for differences in cell 
seeding and growth conditions.  For example, the neurite area of a drug-treated well was 
divided by the average neurite area value from the 5 control images.  To maintain the 
variation in the control, each control value was divided by this normalizing value.  The data 
are reported as fold change in neurite area from control. 
Protein Extractions 
Following drug or vehicle treatment, cells were washed once with warm PBS and 100uL 
extraction buffer (1% Triton-X-100/2M glycerol in 50mM Tris-HCl, 150mM NaCl, + fresh 
protease/phosphatase inhibitors (Thermo Halt, 1X) was added to each well of a 6-well plate. 
The plate was incubated at 37°C for 10 minutes before the extraction buffer was harvested 
from each well to a centrifuge tube and immediately placed on ice.  Samples were cleared 
using centrifugation at 10,000 rpm for 10 minutes and placed back onto ice until gel loading. 
 
Western Blotting 
30ug of crude protein lysates were separated on 8% SDS-PAGE gels and transferred to 
nitrocellulose membranes using a Pierce Power Station with FastBlot semi-dry transfer 
plates.  Briefly, the gel was incubated in water at room temperature for 5 minutes while the 
membrane and filter paper were incubated in Thermo 1-Step Transfer buffer for 5 minutes at 
room temperature before the sandwich was assembled. Excess buffer was removed by 
rolling a glass Pasteur pipette gently across the sandwich and blotting the excess buffer 
around the sandwich with a paper towel.  Protein transfer was performed at 25V at 2.5A for 
12 minutes.  Following transfer, the membrane was washed quickly (5s) in TBST + 0.1% 
Tween-20, and the gel was stained with Coomassie to detect any residual protein.  The 
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membrane was then blocked with blocking buffer (TBST + 0.1% Tween-20 + 5% non-fat 
milk) for 1 hour at 4°C on a plate rocker.  The blocking solution was then discarded and 
fresh blocking solution containing primary antibodies were added and incubated at 4°C 
overnight on a plate rocker.  The following morning, the primary solution was removed and 
the membranes were washed three times with TBST + 0.1% tween (without milk) for 5 
minutes at room temperature.  Fluorophore-conjugated secondary antibodies (Licor700 or 
Licor800) were added at 1:2000 in TBST + 0.1% Tween-20 + 5% milk and incubated at 
room temperature in the dark for 1-2 hours.  The membranes were washed again three times 
with TBST + 0.1% tween (without milk) for 5 minutes each at room temperature and imaged 
on a LI-COR Odyssey Scanner (LI-COR Biosciences, Lincoln, NE). 
 
Results 
Characterization of neurite growth during PC12 differentiation 
After eight days of differentiation, long neurites were present with an average neurite 
length of 200µm/cell (Figure 1B, C).  To establish a neurite area analysis method for rapidly 
analyzing neurite retraction and fragmentation in phase contrast images, we first verified that 
the mean neurite length, sum of neurite lengths, and neurite length per cell measurements in 
untreated cells were equally representative in untreated cells (Figure 1C).  We found these 
metrics were in good agreement, and proceeded with neurite area for the majority of our 
evaluations due to its rapid processing time and its ability to detect fragmentation events. 
 
Paclitaxel and eribulin arrest neurite outgrowth 
Due to the unexpected differences between paclitaxel and eribulin in mice (Chapter 3), 
we compared the effects of each agent on neurite retraction in cultured cells (neurite 
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elongation was not investigated for vincristine and ixabepilone).  To determine 
concentrations at which neurite elongation is inhibited, we treated differentiating PC12 
neurons with either 0.2 nM or 2.0 nM of either paclitaxel or eribulin and acquired phase 
contrast images 1, 3 or 23 hours after drug addition.  While neurites lengthened considerably 
in DMSO treated controls after 23 hours, neurite extension was arrested at 2.0nM of 
paclitaxel and eribulin, but not at 0.2 nM of either drug (Figure 2).  Paclitaxel rapidly 
increased neurite length after 3 hours at 2.0 nM compared to the DMSO control at 3 hours. 
The effect of eribulin was rapid and suppressed outgrowth within 3 hours of treatment.  No 
significant retraction was observed at any concentration, although there was a trend for 
paclitaxel at 23 hours. 
 
Quantification of drug effects on neurite area 
To determine the half maximal inhibitory concentration (IC50) for neurite retraction, we 
treated 8-day differentiated PC12 cells with a range of concentrations of paclitaxel, 
ixabepilone, vincristine, and eribulin for 24 hours and assessed morphology using phase 
contrast microscopy.  Paclitaxel treatment caused a retraction and swelling of neurites, 
although some long neurites remained (Figure 3A).  Ixabepilone was more potent than 
paclitaxel in reducing neurite area, with only 25% of neurite area remaining at the highest 
concentration tested (81 nM).  Vincristine was the most potent agent tested, reducing neurite 
area at low nanomolar concentrations.  Eribulin treatment led to thinning and fragmentation 
of neurites at high concentrations where very few long neurites were still present.  The IC50 
for neurite retraction for each agent was determined from the dose-response curves to be 
11.9, 11.3, 1.9, and 6.0 nM for paclitaxel, ixabepilone, vincristine, and eribulin, respectively 
(Figure 3B  Due to the stimulating effects of paclitaxel and ixabepilone, the IC50 for neurite 
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area was determined to be the concentration that decreased the maximally induced neurite 
area by 50%, which we refer to as the apparent IC50.  For vincristine and eribulin, both 
decreased neurite area at all concentrations tested and the IC50 was determined to be the 
concentration that decreased neurite by 50% from an initial value of 1.  At high 
concentrations (100 nM), both paclitaxel and eribulin directly reduced growth cone 
branching and led to neurite retraction within 1 hour in a live-cell timelapse using phase 
imaging (Figure 4) (vincristine and ixabepilone were not investigated using timelapse 
imaging).  Thinning and fragmentation of neurites was visible after 4 hours in eribulin-
treated cells.   
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Inhibition of undifferentiated PC12 cell proliferation 
All drugs inhibited the number of living cells at nanomolar concentrations, with potency 
as follows: ixabepilone > eribulin > paclitaxel > vincristine (Figure 5) (IC50s 9.7, 14.6, 17, 
21.6 nM, respectively).  Due to the large number of cells that were still alive even at high 
doses of drug after 48 hours, we also calculated the percent of cells remaining for each drug 
as follows: 47%, 37%, 43%, and 34% for ixabepilone, eribulin, paclitaxel, and vincristine, 
respectively.  Finally, there was no correlation between MTA mechanism of action 
(microtubule stabilization or destabilization) and magnitude of IC50. 
 
Comparison of IC50 concentrations for cell proliferation and neurite area. 
Eribulin, vincristine, and paclitaxel all induced neurite retraction (at 24 hours) at lower 
IC50 values than their respective IC50s for PC12 cell proliferation (at 48 hours) (Table 1).  In 
contrast, ixabepilone was more potent in inhibiting PC12 cell proliferation than neurite area.  
In general, the microtubule destabilizing drugs eribulin and vincristine both required higher 
concentrations to inhibit PC12 cell proliferation than previously reported concentrations for 
inhibition of cancer cell proliferation (Smith 2016).  In contrast, the microtubule stabilizing 
drugs paclitaxel and ixabepilone more potently inhibited PC12 cell proliferation than they 
did cancer cells. 
 
Effects of paclitaxel and eribulin on cytosolic α-tubulin abundance and acetylation 
Microtubule polymers are assembled from soluble subunits of α and β-tubulin, and the 
distribution of tubulin is roughly half polymerized in microtubule and half soluble.  
Sufficient levels of cytosolic tubulin are required to provide the building blocks for 
microtubule polymerization. In our previous work, we have shown that both paclitaxel and 
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eribulin treatment of mice in a maximum tolerated dose model induce total α-tubulin and 
tubulin acetylation at K40 in the sciatic nerve (Benbow 2016).  We next asked if paclitaxel 
or eribulin treatment leads to a change in the abundance of cytosolic α-tubulin and acetylated 
tubulin.  To test the effects of paclitaxel and eribulin on cytosolic tubulin abundance and 
acetylation, we treated differentiated PC12 cells with drug concentrations that produced 
neurite retraction and measured the levels of Triton-soluble cytosolic α-tubulin and cytosolic 
acetylated α-tubulin.  A limitation to this approach is that it only provides a picture of what 
is occurring in the soluble pool of α-tubulin (non-cytoskeletal fraction) without providing 
any information on the state of tubulin or abundance of acetylation in the population or 
polymerized tubulin in microtubules (cytoskeletal fraction).  We found that paclitaxel 
markedly depleted levels of cytosolic α-tubulin in a dose-dependent fashion, while levels of 
acetylated α-tubulin were maintained and increased slightly (Figure 6A, B).  In contrast, 
eribulin produced mild depletive effects on α and acetylated tubulin levels at the same 
concentrations (Figure 6C, D). 
 
Microtubule hyperacetylation is not protective against MTA-induced neurite 
retraction 
Previously we found that eribulin treatment of mice in a maximum tolerated dose model 
led to an 11.7-fold induction of total acetylated α-tubulin levels (Benbow 2016).  We 
hypothesized that an increase in acetylation, which was inconsistent with eribulin’s known 
effect of destabilizing microtubules in-vitro, was a possible compensatory response that 
mitigated axonal loss in eribulin treated sciatic nerves (Benbow 2016).  We next asked if 
increasing tubulin acetylation in cells was sufficient to protect neurites from drug-induced 
neurite retraction.  First we verified that tubacin, a small molecule inhibitor of the tubulin 
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deactylating histone deactylase 6 (HDAC6) enzyme, did indeed increase triton-soluble 
(cytosolic) acetylated tubulin in differentiated PC12 cells.  Tubacin increased both cytosolic 
α-tubulin and acetylated α-tubulin at micromolar concentrations after 24 hours of treatment 
(Figure 7A, B).  Immunofluorescent microscopy confirmed an increase in K40 tubulin 
acetylation (Figure 7C).  Tubulin acetylation in DMSO treated controls was primarily 
localized to neurites with very little signal found in cell bodies.  Microscopy images did not 
provide sufficient resolution to discern whether the acetylated tubulin was cytoskeletal-
associated or soluble due to the dense bundling of microtubules in neurites.  Following 
treatment with tubacin, the increase in acetylation was most significant in the cell bodies 
with a slight increase in neurites.  After confirming that tubacin treatment alone did not 
result in neurite retraction (Figure 7E), we pretreated differentiated PC12 cells with 6uM of 
tubacin for 24 hours to hyperacetylate tubulin before adding concentrations of paclitaxel and 
eribulin that produced reproducible effects on neurite area.  Each agent was added to cultures 
without removing tubacin and neurite area was measured 24 hours following (Figure 7D).  
We found that tubacin pre-treatment failed to protect neurites from paclitaxel or eribulin 
induced neurite retraction (Figure 7F). 
 
Discussion 
To improve our understanding of the molecular mechanisms involved in regulating 
neurite loss in response to treatment with microtubule targeting agents, we characterized the 
effects of MTAs on differentiated PC12 neurite morphology and tubulin biochemistry.  We 
found that treatment with both microtubule stabilizers and destabilizers led to neurite loss at 
generally lower concentrations of MTAs than were required for inhibition of PC12 cell 
proliferation.  Further, there was a trend for destabilizing agents to require higher 
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concentrations to inhibit cell proliferation of PC12 cells than did microtubule stabilizing 
drugs, as compared to reported cancer cells IC50s.  Taken together, the post-mitotic 
population of microtubules in neurites of neuronal cells is more susceptible to the 
mechanism of action of MTAs. These findings are consistent with recent findings of the 
effects of paclitaxel, vincristine, and eribulin’s effects on neurites per cell in an immortalized 
DRG cell culture model (Smith 2017, manuscript in preparation). 
The drug-specific effects of shorter and swollen neurites in paclitaxel-treated cells and 
thinning and fragmentation in eribulin-treated cells are consistent with each of their known 
mechanisms of in-vitro action of stabilization and destabilization, respectively.  In movies of 
neurite retraction with either 100pM paclitaxel or eribulin, the initial effects on growth cone 
branching are apparent within 1 hour (Figure 4).  Given the importance of the cytoskeleton 
for growth cone dynamics in growing neurites, the repercussions of eribulin’s microtubule 
destabilization are easy to understand in the context of microtubule, and thus, neurite loss.  
However, stabilization of the entire cytoskeleton via paclitaxel treatment also leads to 
neurite retraction.  This contradictory result indicates that the level of microtubule stability 
and dynamics must be operating within a narrow window and that neurite loss occurs when 
the equilibrium is tipped in either direction.  Consequently, low concentrations (<3 nM) of 
both paclitaxel and ixabepilone led to an increase in neurite area, with ixabepilone having a 
slightly stronger effect.  However, neurite area was reduced at concentrations above 3 nM, 
indicating that the threshold for apparent beneficial stabilization of the microtubule 
cytoskeleton had been crossed.   Due to the increase in neurite area in paclitaxel and 
ixabepilone treated cells, we calculated the half maximal inhibitory concentration by 
assuming that the maximally induced neurite area occurred at the lowest tested concentration 
of 1nM.  If lower concentrations led to even greater increases in neurite area, then we would 
  124 
expect the actual IC50 for inhibition of neurite area to be even lower.  Therefore we assume 
that the apparent IC50s we identify from the curve are at their maximal magnitudes.  We also 
assume that at higher concentrations than tested (81 nM), paclitaxel reduces neurite area to 
zero.  Based on these assumptions we report the apparent IC50s for neurite area for 
paclitaxel and ixabepilone.   The IC50 ratio of neurite area to cancer cell proliferation for 
each drug was 7.5, 0.95, 1.08, and 1.51 for eribulin, vincristine, ixabepilone, and paclitaxel, 
respectively.   This means that eribulin was 7.5 times more potent at inhibiting cancer cell 
proliferation than it was at reducing neurite area. Vincristine, on the other hand, required an 
almost equivalent concentration (ratio = 0.95).   It is tempting to speculate that this 
differential susceptibility of neurites to MTAs is the basis for the differential induction of 
clinically severe neuropathy. 
The lack of difference among IC50 values for neurite area is striking when compared to 
the sensitivity of cancer cells to eribulin.  For example, eribulin is used clinically at 1.4 
mg/m
2 
per cycle, about 142 times less than the average patient dose per cycle of paclitaxel 
(200 mg/m
2
).  Yet the concentrations that reduce neurite area are only 2-fold different for 
these two drugs.  This may mean that axonal microtubules in neurons and cancer cells 
respond very differently to microtubule inhibition because they are expressing different 
microtubule-associated proteins, post-translational modifications, or tubulin isotypes. 
The result that cytosolic tubulin is depleted at paclitaxel concentrations that cause neurite 
retraction supports a model in which an accumulation of microtubule bundles inhibits cell 
function.  At nanomolar paclitaxel concentrations that block mitosis in HELA cells, the mass 
of microtubule polymer comprises about half of the total tubulin in cells (Jamieson 2007).  
However, as paclitaxel concentration is increased, the mass of microtubules increases about 
5-fold, leading to extensive bundling and the need for additional tubulin synthesis to 
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maintain cytosolic tubulin at a high enough concentration to supply the dynamic activities of 
non-bundled microtubules.  The presence of massive bundles in paclitaxel-treated neurites 
may overcome the cell’s ability to replenish tubulin protein or inhibit other microtubule-
active proteins.  Soluble tubulin is known to play a role in prevention of mitochondrial 
depolarization through interactions with α-tubulin’s C-terminal tail and the VDAC channel 
of mitochondria outer membranes (Rostovtseva et al. 2008).  When soluble tubulin is 
depleted from the cytosol, mitochondria are allowed to initiate apoptosis.  Recent evidence 
supports a model in which cytosolic α-tubulin operates as a homeostat for microtubule health 
(and in turn general cell health) by regulating the mitochondria apoptotic response (Carre´ et 
al. 2001, Israelson et al. 2006, Barrientos et al. 2011). 
The finding that increased levels of tubulin acetylation are not sufficient to protect 
against MTA-induced neurite loss suggests additional roles of α-tubulin acetylation in 
neurite stability.  An important caveat of this finding is that the tubulin evaluations 
performed here were focused on the cysolic (Triton-soluble = noncytoskeletal associated) 
fraction of tubulin and not the microtubule (cytoskeletal associated) population of tubulin.  
Therefore we cannot conclude anything about the acetylation state of polymerized tubulin 
because microtubule polymers are not soluble in Triton-X-100 extracts.  Further experiments 
should include an additional fractionation step for isolating the cytoskeletal associated 
population of tubulin to show changes in acetylation with respect to both microtubule 
associated and non-associated tubulin.  A further understanding of how acetylation is 
involved in microtubule stability, either through local structural changes in the microtubule 
lattice or by the recruitment of other MAPS, will provide insight into the regulation of 
microtubule dynamics in populations of post-mitotic microtubules. A second caveat of this 
work is the method in which acetylation was increased by pharmacological inhibition of the 
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HDAC6 enzyme.  While tubacin is a useful molecule for studying the effects of HDAC6 
inhibition, evidence suggests that other proteins, such as β-tubulin and tau, are also 
acetylated (Chu et al., 2011).  Thus is it difficult to conclude that the only effect of HDAC6 
inhibition via tubacin is α-tubulin hyperacetylation.  Further experiments should focus on 
specific overexpression of the tubulin acetylating enzyme αTAT1 to increase acetylation of 
microtubules specifically without off-target effects of inhibiting deacetylating enzymes.   
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  128 
Figure 1. PC12 differentiation by nerve growth factor and dbcAMP over eight days in 5% 
HI-horse serum and 5% calf serum-containing media at 37C and 5% CO2. A, Schedule of 
cell culture conditions.  dbcAMP is added three hours post-seeding, then NGF is added to 
existing media 24 hours later and every other day following.  A half media change can be 
performed on day 5 if necessary, but may not be required.  B, Representative 10X phase 
contrast images of PC12 cells corresponding to each day of the schedule shown in A, scale 
bar = 100 μm. C, Neurite length and area measurements over eight days of differentiation. 
Measurements are from five images per timepoint.  From left to right, the graphs represent 
the average length or area of all neurites per image for five images, the sum of the total 
neurite length or area for five images, and the average neurite length or area per cell (total 
value divided by the number of cell bodies in the corresponding image).  Bar graphs are 
mean ± SEM, produced in GraphPad Prism. 
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Figure 2. Low nanomolar concentrations of paclitaxel and eribulin arrest neurite 
outgrowth.  8-day differentiated PC12 cells were treated with either 0.2nM or 2.0nM of 
paclitaxel (16% IC50 for neurite area at 24 hours) or eribulin (30% IC50 for neurite area at 24 
hours) for 3, 5, and 23 hours.  At each timepoint, phase contrast images were taken and 
neurite lengths were analyzed from at least 5 images for each condition and averaged.  For 
each drug, 2.0nM was sufficient to arrest neurite outgrowth. 
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Figure 3. Quantification of drug effects on neurite area of cultured PC12 neurons.  
Differentiated PC12 cells were treated with each agent for 24 hours before taking phase 
contrast images and neurite area measurements. A, representative images of each agent’s 
effects on neurite morphology.  B, Quantification of neurite area after treatment with either 
paclitaxel, ixabepilone, vincristine, or eribulin. Student’s T-tests from DMSO control * = 
P<0.05, ** = P<0.01, *** P<0.001. 
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Figure 4. Paclitaxel or eribulin treatment rapidly reduces growth cone branching and 
leads to neurite retraction.  8 day differentiated PC12 cells were treated with 100pM of 
either eribulin or paclitaxel and imaged live at 37°C/5% CO2 over the course of 4 hours 
using phase contrast microscopy.  The red arrows indicate growth cones that display 
retraction over the time course. 
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Figure 5. Dose-response for number of live undifferentiated PC12 cells 48 hours after drug 
addition.  PC12 cells will continue to divide until differentiation is initiated by addition of 
dbcAMP/NGF (the time of cell division is about 48 hours).  All drugs decreased the number 
of living cells, with potency as follows: Ixabepilone > Eribulin > Paclitaxel > Vincristine. 
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Table 1. Summary of IC50 values for cell proliferation and neurite area 
Drug 
Effect on 
Microtubules 
IC50 Values (nM) 
 Neurite 
Area/Proliferation 
IC50 Ratios Cancer Cells  
Neuronal PC12 Cells 
 
Proliferation   Proliferation 
Neurite 
area 
  
Neuronal 
PC12 
cells 
Cancer 
Cells 
Eribulin Destabilizes 0.8 
 
14.6 6 
 
0.41 7.50 
Vincristine Destabilizes 2 
 
21.6 1.9 
 
0.09 0.95 
Paclitaxel Stabilizes 11 
 
17 11.9* 
 
0.70 1.08 
Ixabepilone Stabilizes 7.5   9.7 11.3*   1.16 1.51 
 
*Apparent IC50 for neurite area.
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Figure 6. Paclitaxel was more potent in altering the abundance and acetylation of 
cytosolic (non-cytoskeletal associated) tubulin.  Differentiated PC12 cells were treated 
with either paclitaxel or eribulin for 24 hours.  Extraction buffer containing TritonX-100 
detergent was used to collect the cytosolic fraction of tubulin from the cells.  A, paclitaxel 
depletes α-tubulin from the non-cytoskeletal fraction and increases the acetylated of soluble 
tubulin in western blots for α-tubulin, acetylated α-tubulin, and GAPDH.  B, Quantification 
of protein abundance normalized to the GAPDH loading control.  C, Eribulin, in contrast, 
had mild effects on the abundance of α- and acetylated α-tubulin in the Triton-soluble 
protein fraction. 
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Figure 7. Pretreated with tubacin does not protect from paclitaxel or eribulin-induced 
neurite retraction of PC12 cells.  A, Treatment of differentiated PC12 cells with tubacin, a 
small molecule inhibitor of HDAC6, increases acetylation of soluble tubulin.  B, 
Quantification of the fold change of α and acetylated tubulin from the DMSO-treated 
control.  C, The intensity and distribution of acetylated tubulin in fluorescence microscopy 
images with anti-K40Ac antibody.  D, Representative phase contrast images after treatment 
with the indicated agents. E, Dose response of neurite area to tubacin alone.  F, 
Quantification of neurite area after treatment with conditions in D.    
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VI. General Conclusions and Future Directions 
At the outset of the work presented here, it was unknown in the field how peripheral 
axons responded morphologically and biochemically to treatment with agents that perturb 
microtubules, and if their effects correlated with the severity of neuropathy.  We found that 
for the commonly used chemotherapies paclitaxel and eribulin the morphological effects 
reflect their respective rates of severe neuropathy and that eribulin induced interesting 
biochemical changes that may reflect compensatory responses of neurons to microtubule 
inhibition.  This was a novel idea and illustrates our lack of understand of the mechanisms 
involved in axonal microtubule maintenance.  Our initial work was the first to describe the 
changes in axonal α-tubulin abundance and acetylation in peripheral axons upon treatment 
with these agents.  We inferred the state of microtubule stability using these measurements 
and speculated that eribulin is unique in that it does induce morphological deficits but that 
the positive biochemical changes create a more stable and functional microtubule 
cytoskeleton.  This work was important because it allowed us to compare multiple agents 
with known in-vitro effects on microtubules with their effects on dynamics in a living 
animal.   
Understanding the mechanisms of axonal microtubule maintenance has implications 
in many neurodegenerative diseases where microtubule dynamics or mass is affected.  Our 
group has contributed the first systematic study on the recovery from these agents in a mouse 
model and found that paclitaxel induces long-lasting changes through yet unknown 
mechanisms.  The field may now recognize the importance of compensatory mechanisms 
that regulate the onset, progression, and recovery from neuropathy.  The microtubule-based 
approach our group has taken illustrates the importance in recognizing that microtubule 
targeting agents may affect microtubules in a complex system such as a neuron differently 
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than they would in purified in-vitro systems over short durations.  If I were to remain in the 
field my primary research focus would the identification of molecular players that monitor 
and respond to alterations in axonal microtubule dynamics.  For example, upon treatment 
with paclitaxel, how does the cell detect and respond to microtubule stabilization?  Which 
pathways are activated?  Does it involve active processes of axon degeneration or passive 
neurotrophic atrophy?  The establishment of an in-vitro cell culture model in this work is a 
first step in this direction as cells better recapitulate the complex environment of the 
peripheral nervous system than purified systems.   
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